WO2002036626A1 - Polypeptides multimeres comportant une seule chaine - Google Patents

Polypeptides multimeres comportant une seule chaine Download PDF

Info

Publication number
WO2002036626A1
WO2002036626A1 PCT/DK2001/000724 DK0100724W WO0236626A1 WO 2002036626 A1 WO2002036626 A1 WO 2002036626A1 DK 0100724 W DK0100724 W DK 0100724W WO 0236626 A1 WO0236626 A1 WO 0236626A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
csf
chain
amino acid
conjugate
Prior art date
Application number
PCT/DK2001/000724
Other languages
English (en)
Inventor
Torben Lauesgaard Nissen
Anne Dam Jensen
Original Assignee
Maxygen Aps
Maxygen Holdings Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Aps, Maxygen Holdings Ltd. filed Critical Maxygen Aps
Priority to AU2002212108A priority Critical patent/AU2002212108A1/en
Priority to EP01980207A priority patent/EP1334127A1/fr
Publication of WO2002036626A1 publication Critical patent/WO2002036626A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to single-chain multimeric polypeptides and polypep- tide conjugates, in particular to multimeric cytokine polypeptides comprising at least two monomeric units of a cytokine polypeptide of a type that normally is biologically active in monomeric form.
  • biopharmaceuticals such as granulocyte colony stimulating factor, erythropoietin, interferons, interleukins, growth hormones and factors and coagulation factors mediate their effect on cells by binding to specific receptors on cell surfaces, whereby cytokine-receptor complexes are formed that activate certain signal transduction pathways in the cells.
  • the cytokines bind to their receptors as monomers or as multimers, e.g. dimers, trimers or tetramers.
  • cytokine pharmaceuticals and other injected protein pharmaceuticals suffer from the problem of an insufficient plasma half-life in the body, so that injections must be made relatively frequently in order to maintain a sufficient level of the protein in vivo. This is disadvantageous since it is both inconvenient for the patient and costly, and it is therefore often desirable to be able to increase the plasma half -life of protein pharmaceuticals.
  • Various approaches have been used with the aim of increasing the plasma half -life of such proteins. Since it is known that increasing the size of the protein generally tends to increase the plasma half -life, several of these approaches have involved increasing the molecular weight by various means.
  • scJ -5 single-chain interleukin 5
  • Human interleukin 5 is biologically active as a disulfide-linked homodimer
  • the scIL-5 mutants of Li et al. were based on scIL-5 constructed by linking two TL-5 monomers with a Gly-Gly linker.
  • Leong et al. ⁇ Protein Sci. 6(3): 609-17, Mar. 1997) disclose single-chain dimers of interleukin 8 linked via a peptide linker and with a single disulfide crosslink to prevent formation of multimers.
  • the single-chain IL-8 dimers were designed to mimic the dimeric form of IL-8 in solution with the aim of producing heterodimer IL-8 variants.
  • Randal et al. disclose a single-chain variant of human interferon-gamma (IFN- ⁇ ) in which two IFN- ⁇ chains are linked with an eight residue polypeptide linker.
  • Landar et al. disclose a biologically active single-chain mutant of IFN- ⁇ produced by linking the two peptide chains of IFN- ⁇ with a seven-residue linker and by mutating Hisl 11 in the first chain.
  • WO 98/27230 discloses various methods for polypeptide engineering using recursive sequence recombination (RSR), including single-chain versions of multisubunit factor proteins.
  • RSR recursive sequence recombination
  • Multimeric polypeptides with polypeptide units joined by a cleavable linkage have also been disclosed for the purpose of producing monomeric polypeptides.
  • WO 00/17336 discloses a DNA cassette comprising two or more tandem repeating units of a nucleotide sequence encoding a biologically active short peptide attached to a linker peptide cleavable by a protease or a chemical agent. Expression of the DNA cassette results in a multimeric polypeptide that is subsequently cleaved enzymatically or chemically to result in the desired biologically active peptide.
  • US 5,218,093 discloses biologically active variants of epidermal growth factor (EGF) comprising at least two monomeric EGF units that may be linked either by direct C- terminus to N-terminus fusion or through a cleavage-insensitive peptide linker.
  • EGF epidermal growth factor
  • Human EGF is a monomeric protein having 53 amino acid residues, and the problem addressed by US 5,218,093 is that of preventing undesired intracellular degradation by native proteases found in the recombinant microbial hosts used to produce recombinant EGF.
  • this document avoids the need to produce recombinant EGF as a fusion protein bound to a stabilizing carrier, which requires subsequent downstream processing to release the EGF in monomeric form, or to produce EGF in multimeric form with repeating units linked through a cleavage-sensitive site that is subsequently digested using a site-specific enzyme. It is disclosed that the multimeric EGF has biological activity characteristic of monomeric EGF, but no other advantages aside from those specifically related to the production process are described.
  • US 5,684,136 discloses a method for receptor activation by providing a conjugate comprising the direct fusion of a first ligand and a second ligand capable of binding to first and second receptors, and contacting the conjugate with the first and second receptors.
  • the conjugate is in particular a chimeric molecule comprising a dimer of hepatocyte growth factor (HGF), a disulfide-linked heterodimer comprising a 69 kDa alpha subunit and a 34 kDa beta subunit.
  • HGF hepatocyte growth factor
  • WO 99/38891 discloses modified polypeptides with increased biological activity, in particular modified erythropoietin (EPO), in the form of multimeric polypeptides with polypeptide units covalently linked by thioester bonds.
  • EPO modified erythropoietin
  • WO 99/02710 discloses recombinant fusion protein multimers with altered biological activity such as increased plasma half-life, comprising two or more protein molecules fused directly or via a peptide linker, in particular modified EPO. This document teaches against conjugating proteins to chemical compounds or inert molecules as a way to increase biological activity, as this is said to often result in a significant decrease in the overall biological activity.
  • WO 92/06116 discloses a recombinant hematopoietic molecule comprising at least a portion of a first hematopoietic molecule having early myeloid differentiation activity and at least a portion of a second hematopoietic molecule having late myeloid differentiation activity, the recombinant hematopoietic molecule having early myeloid differentiation activity associated with the first hematopoietic molecule and late myeloid differentiation activity associated with the second hematopoietic molecule.
  • the first hematopoietic molecule may be IL-3 or GM-CSF
  • the second hematopoietic molecule may be EPO, G-CSF, IL-5 or M-CSF.
  • WO 01/03737 discloses fusion proteins comprising a cytokine or growth factor fused to an immunoglobulin domain, in particular IgG. Also dis- closed are multimeric fusion proteins comprising two or more members of the growth hormone superfamily joined with or without a peptide linker, although no such multimeric fusion proteins are actually exemplified.
  • Paige et al. disclose prolonged circulation of recombinant human granulocyte-colony stimulating factor (rhG-CSF) by covalently linking rhG-CSF to serum albumin through a heterobifunctional maleimido-carboxyl polyethylene glycol.
  • rhG-CSF human granulocyte-colony stimulating factor
  • the present invention provides single-chain multimeric polypeptides with advantageous biological properties based on monomeric units of a polypeptide of a type that nor- mally is biologically active in monomeric form, in particular based on polypeptide units that in their native form are non-glycosylated or have a relatively low degree of glycosylation.
  • the present invention relates to single-chain multimeric poly- peptides and polypeptide conjugates, in particular polypeptides and conjugates exhibiting agonist activity, comprising at least two monomeric units of a polypeptide of a type that is biologically active in monomeric form, as well as methods for preparation of the polypeptides and their use in medical treatment.
  • one aspect of the invention relates to single-chain multimeric poly- peptide conjugate comprising at least two units of a monomeric polypeptide linked via a peptide bond or a peptide linker, wherein the monomeric polypeptide is of a type that is biologically active in monomeric form, and having at least one polymer moiety covalently bound to an attachment group of said polypeptide.
  • Another aspect of the invention relates to a single-chain multimeric polypeptide conjugate comprising at least two units of a monomeric polypeptide linked via a peptide bond or a peptide linker, wherein the monomeric polypeptide is of a type that is biologically active in monomeric form, and wherein at least one of said units differs from the corresponding wild-type polypeptide in that at least one amino acid residue comprising an attachment group for a non-polypeptide moiety has been introduced or removed, and having at least one non-polypeptide moiety covalently bound to an attachment group of said polypeptide.
  • a further aspect of the invention relate to nucleotide sequences encoding the single- chain polypeptides, expression vectors and host cells comprising such a nucleotide sequence and a method for preparing the polypeptides and conjugates by recombinant DNA techniques.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a polypeptide or conjugate of the invention together with a pharmaceutically accept- able excipient or vehicle, the use in therapy of a single-chain polypeptide or conjugate of the invention, and a method of treating a mammal using a single-chain polypeptide or conjugate of the invention.
  • Figure 1 shows the in vivo biological activity of single-chain G-CSF dimers in healthy rats.
  • Figure 2 shows the in vivo biological activity of single-chain G-CSF dimers in rats with chemotherapy-induced neutropenia.
  • polypeptide is understood to indicate a mature protein or a precursor form thereof as well as a functional fragment thereof which essentially has retained the activity of the mature protein, i.e. exhibits at least the same qualitative activity and preferably also at least a similar quantitative activity as the mature protein.
  • a functional fragment may for instance be an N- and/or C-terminal truncated form of a full-length polypeptide, or an isoform, in particular a native isoform, of a full-length polypeptide.
  • the monomeric subunits of the polypeptides of the invention are derived from or otherwise made so as to mimic the structure and function of parent polypeptides which in their native form are biologically active as monomers, i.e.
  • the parent polypeptides do not normally require formation of dimers, trimers, etc. in order to be biologically active in vivo.
  • the term "derived” is intended to indicate that the monomeric polypeptide subunit is prepared to mimic structural and/or functional properties of the corresponding native polypeptide in question.
  • the "derived" polypeptide may have the same amino acid sequence as said native polypeptide, or it may have one or more amino acid changes, e.g. those made in accordance with the present invention.
  • the amino acid sequence of the "derived" polypeptide is at least 60% identical (homologous) to that of said native polypeptide, normally at least 70% identical, such as at least 80% or at least 90% or 95% identical.
  • the monomeric polypeptides used in the present invention are of mammalian origin, in particular of human origin. It will be understood that derived polypeptides include synthetic polypeptides with the necessary structural and/or functional similarity to a native polypeptide.
  • parent polypeptide is used about the monomeric polypeptide, which in accordance with the present invention is provided in a modified single-chain form comprising two or more monomers.
  • the individual monomers are linked by peptide bonds, optionally through a linker peptide, rather than being linked by non-covalent bonds or disulfide bonds.
  • the single-chain polypeptides of the invention are expressed as a single polypeptide from a single nucleotide sequence rather than being expressed as single mono- mer molecules which are assembled to an oligomeric polypeptide only after expression.
  • the parent monomer may be a wild-type monomeric polypeptide or a variant thereof, for instance a mutein form of the wild-type monomeric polypeptide which has been prepared by substitution or deletion of one or more amino acid residues thereof and/or insertion of one or more additional amino acid residues therein.
  • multimeric or “oligomeric” polypeptide is merely intended to indicate that the polypeptide comprises two or more monomeric units that are linked together, (i.e. to form a dimer, trimer, tetramer., etc.) since, strictly speaking, the sin- gle-chain polypeptides of the invention cannot be said to be multimeric.
  • the terms "dimer”, “dimeric”, “trimer”, “trimeric”, etc. are used in the same manner.
  • signaling polypeptide is used to denote a polypeptide that interacts with a cellular receptor so as to activate the receptor and thereby provide a signal initiating a signal transduction cascade in the cell carrying the receptor.
  • a polypeptide is often also termed a ligand.
  • an "agonist” is a molecule which is capable of binding to a desired receptor to result in an activated receptor complex.
  • An “antagonist” on the other hand is a molecule which is capable of binding to a desired receptor but incapable of mediating correct conformational changes of the receptor molecules necessary to result in an activated complex, whereby ligand-mediated receptor activation is substantially inhibited.
  • Receptor activation upon binding of a suitable ligand generally involves conformational change in the receptor, e.g. oligomerisation of receptor subunits.
  • a polypeptide of the invention "having agonist activity" refers to the fact that the multimeric polypeptides are able to bind to and activate at least one cellular receptor via at least one monomeric subunit, where said subunit typically is derived from or identical to a native agonist polypeptide having a similar agonist activity.
  • the invention is primarily directed to polypeptides and conjugates that have agonist activity, it is also contemplated that the principles of the invention will be equally applicable to single-chain multimeric antagonist polypeptides, i.e. in which at least one monomeric unit of the polypeptide is able to bind to a target receptor without activating the receptor.
  • ligand-binding domain refers to the part or parts of a cellular receptor which is/are involved in specific recognition of and interaction with a receptor-binding site of an endogenous ligand.
  • the "receptor-binding site” is understood as those amino acid residues which are involved in polypeptide binding to the ligand-binding domain of the receptor. Normally, the receptor-binding site comprises 1-50 amino acid residues, such as 5-30 or 10-25 amino acid residues. The amino acid residues in question may be located in sequence, but are more often placed in spatial proximity to each other as a result of the folding of the polypeptide. In the Materials and Methods section below, a method is described for determining residues of a receptor-binding site.
  • receptor is understood to indicate a protein present on a cell surface which binds signalling molecules (i.e. ligands) as the first step in triggering the signal transduction cascade.
  • Cell surface receptors are typically composed of different domains with different functions, such as an extracellular ligand-binding domain with which the signalling polypeptide interacts to initiate signal transduction, a transmembrane domain (or in some cases, several transmembrane domains) which anchors the receptor in the cell membrane, and an intracellular effector domain which generates a cellular signal in response to ligand binding (signal transduction).
  • conjugated polypeptide is intended to indicate a composite or chimeric molecule formed by the covalent attachment of one or more polypeptides to one or more non-peptide moieties.
  • covalent attachment means that the polypeptide and the non-peptide moiety are either directly covalently joined to one another, or else are indirectly covalently joined to one another through an intervening moiety or moieties, such as a bridge, spacer, or linkage moiety or moieties.
  • the conjugated polypeptide is soluble at relevant concentrations and conditions, i.e. soluble in physiological fluids such as blood.
  • conjugated polypeptides of the invention include glycosylated polypeptides and PEGylated polypeptides.
  • the term “non-conjugated polypeptide” can be used about the polypeptide part of the conjugate.
  • non-peptide moiety is intended to indicate a molecule which is not a peptide and which is capable of conjugating to an attachment group of the polypeptide of the invention.
  • Preferred examples of such molecule include polymers, e.g. polyalkylene oxide, oligosaccharide moieties, lipophilic groups, e.g. fatty acids, and ceramides.
  • polymer molecule is a molecule formed by covalent linkage of two or more monomers, wherein none of the monomers is an amino acid residue, except where the polymer is human albumin or another abundant plasma protein.
  • polymer may be used interchangeably with the term “polymer molecule”. Except where the number of polymer molecules is expressly indicated, every reference to "a polymer”, “a polymer molecule”, “the polymer” or “the polymer molecule” contained in a polypeptide of the invention or otherwise used in the pre- sent invention shall be a reference to one or more polymer molecules.
  • oligosaccharide moiety is intended to indicate a carbohydrate- containing molecule comprising two or more monosaccharide residues, and which is capable of being attached to the polypeptide to produce a polypeptide conjugate in the form of a glycosylated polypeptide by way of in vivo or in vitro glycosylation.
  • in vivo glycosy- lation is intended to mean any attachment of an oligosaccharide moiety occurring in vivo, i.e. during posttranslational processing in a glycosylating cell used for expression of the polypeptide, e.g. by way of N-linked and O-linked glycosylation.
  • the N- glycosylated oligosaccharide moiety has a common basic core structure composed of five monosaccharide residues, namely two N-acetylglucosamine residues and three mannose residues.
  • the exact oligosaccharide structure depends, to a large extent, on the glycosylating organism in question and on the specific polypeptide.
  • the glycosylation may be classified as a high mannose type, a complex type or a hybrid type.
  • in vitro glycosylation is intended to refer to a synthetic glycosylation performed in vitro, normally involving covalently linking an oligosaccharide moiety to an attachment group of a polypeptide, optionally using a cross-linking agent. In vivo and in vitro glycosylation are discussed in detail further below.
  • oligosaccharide moieties are considered separately from “polymer molecules” as defined above, i.e. the term “polymer moiety” as used herein is not intended to encompass oligosaccharide moieties.
  • a polypeptide conjugate of the invention comprising one or more oligosaccharide moieties bound to an attachment group of a polypeptide, e.g. by way of in vivo glycosylation, may in addition comprise one or more polymer moieties bound to an attachment group of the polypeptide, e.g. by way of PEGylation.
  • the multimeric polypeptide conjugate of the invention is one in which at least one monomeric polypeptide unit is non-glycosylated or is glycosylated at one, two or three amino acid residues, the glycosyl moieties typically having a molecular weight of about 1-10 kDa, more typically 1-6 kDa.. In many cases, this will apply to all of the monomeric units.
  • the monomeric polypeptide units of the invention will be derived from monomeric polypeptides that in their native form are non-glycosylated or have a relatively low degree of glycosylation (a low degree of glycosylation being understood in the present context as glycosylation at not more than three sites on a monomeric polypeptide).
  • N-glycosylation site has the sequence N-X'-S/T/C-X", wherein X' is any amino acid residue except proline, X' ' is any amino acid residue that may or may not be identical to X' and preferably is different from proline, N is asparagine and S/T/C is either serine, threonine or cysteine, preferably serine or threonine, and most preferably threonine.
  • An "O-glycosylation site” is the OH-group of a serine or threonine residue.
  • attachment group is intended to indicate a functional group of the polypeptide, in particular of an amino acid residue thereof or an oligosaccharide moiety, capable of attaching a non-peptide moiety such as a polymer molecule, a lipophilic molecule or an organic derivatizing agent.
  • a non-peptide moiety such as a polymer molecule, a lipophilic molecule or an organic derivatizing agent.
  • attachment group is used to indicate the amino acid residues that together constitute an N-glycosylation site.
  • asparagine residue of the N-glycosylation site is where the oligosaccharide moiety is attached during glycosylation, such attachment cannot be achieved unless the other amino acid residues of the N-glycosylation site are present.
  • amino acid residue comprising an attachment group for the non-peptide moiety is to be understood as meaning that one or more amino acid residues constituting an N-glycosylation site are to be altered in such a manner that either a functional N-glycosylation site is introduced into the amino acid sequence or removed from said sequence.
  • attachment group is intended to mean that the attachment group is present on an amino acid residue (including an N-glycosylation site) of the relevant peptide or polypeptide or on an oligosaccharide moiety attached to said peptide or polypeptide.
  • Amino acid names and atom names are used herein as defined by the Protein DataBank (PDB) (www.pdb.org), which is based on the IUPAC nomenclature (IUPAC Nomenclature and Symbolism for Amino Acids and Peptides (residue names, atom names, etc.), Eur. J. Biochem., 138, 9-37 (1984) together with their corrections in Eur. J. Biochem., 152, 1 (1985).
  • the term "amino acid residue” is intended to indicate an amino acid residue contained in the group consisting of the 20 naturally occurring amino acids, i.e.
  • alanine (Ala or A), cysteine (Cys or C), aspartic acid (Asp or D), glu- tamic acid (Glu or E), phenylalanine (Phe or F), glycine (Gly or G), histidine (His or H), isoleucine (Tie or I), lysine (Lys or K), leucine (Leu or L), methionine (Met or M), asparagine (Asn or N), proline (Pro or P), glutamine (Gin or Q), arginine (Arg or R), serine (Ser or S), threonine (Thr or T), valine (Val or V), tryptophan (Trp or W) and tyrosine (Tyr or Y).
  • T13 in a given amino acid sequence indicates position number 13 occupied by a threonine residue.
  • T13K indicates that the threonine residue of position 13 has been substituted by a lysine residue.
  • Multiple substitutions are indicated with a "+", e.g. S93N+G95S/T means an amino acid sequence which comprises substitution of the serine residue in position 93 by an asparagine residue and substitution of the glycine residue in position 95 by a serine or a threonine residue.
  • nucleotide sequence is intended to indicate a consecutive stretch of two or more nucleotide molecules.
  • the nucleotide sequence may be of genomic, cDNA, RNA, semi-synthetic or synthetic origin, or any combination thereof.
  • Cell “host cell”, “cell line” and “cell culture” are used interchangeably herein and all such terms should be understood to include progeny resulting from growth or cultur- ing of a cell.
  • Transformation and “transfection” are used interchangeably to refer to the process of introducing DNA into a cell.
  • operably linked refers to the covalent joining of two or more nucleotide se- quences in such a manner that the normal function of the sequences can be performed.
  • the nucleotide sequence encoding a presequence or secretory leader is operably linked to a nucleotide sequence for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide: a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence.
  • introduction is primarily intended to mean substitution of an existing amino acid residue, but may also mean insertion of an additional amino acid residue.
  • the term “remove” is primarily intended to mean substitution of the amino acid residue to be removed by another amino acid residue, but may also mean deletion (without substitution) of the amino acid residue to be removed.
  • reduced immunogenicity is intended to indicate that the conjugate gives rise to a measurably lower immune response than a reference molecule, e.g. a wild-type polypeptide, as determined under comparable conditions.
  • the immune response may be a cell or antibody mediated response (see, e.g., Roitt: Essential Immunology (8th Edition, Blackwell) for further definition of immunogenicity). Normally, reduced antibody reactivity will be an indication of reduced immunogenicity.
  • the reduced immunogenicity may be determined by use of any suitable method known in the art, e.g. in vivo or in vitro.
  • the term "functional in vivo half -life” is used in its normal meaning, i.e. the time at which 50% of the biological activity of the polypeptide or conjugate is still present in the body/target organ, or the time at which the activity of the polypeptide or conjugate is 50% of the initial value.
  • "serum half- life” may be determined, i.e. the time in which 50% of the polypeptide or conjugate molecules circulate in the plasma or bloodstream prior to being cleared. Determination of serum half-life is often more simple than determining the functional in vivo half-life, and the magnitude of serum half-life is usually a good indication of the magnitude of functional in vivo half -life.
  • serum half-life alternatives include “plasma half-life”, “circulating half- life”, “serum clearance”, “plasma clearance” and “clearance half -life”.
  • the polypeptide or conjugate is cleared by the action of one or more of the reticuloendothelial systems (RES), kidney, spleen or liver, by receptor-mediated degradation, or by specific or non-specific pro- teolysis.
  • RES reticuloendothelial systems
  • clearance is believed to be primarily determined by the level of renal clearance and receptor-mediated clearance, while e.g. nonspecific proteolysis is believed to be of secondary importance.
  • clearance depends on size (relative to the cutoff for glomerular filtration), charge, attached carbohydrate chains, the presence of cellular receptors for the protein and the affinity of the protein towards its receptor(s).
  • the functional in vivo half -life and the serum half -life may be determined by any suitable method known in the art, e.g. by the method disclosed in US 5,824,778.
  • the term "increased" as used about the functional in vivo half-life or serum half-life is used to indicate that the relevant half -life of the conjugate or polypeptide is statistically significantly increased relative to that of a reference molecule, e.g. a corresponding wild- type or non-conjugated monomeric polypeptide, as determined under comparable conditions.
  • the relevant half-life may increased by at least 25%, such as by at least 50%, by at least 100%, or by at least 500% or 1000%.
  • Renal clearance is used in its normal meaning to indicate any clearance taking place by the kidneys, e.g. by glomerular filtration, tubular excretion or tubular elimination. Renal clearance depends on physical characteristics of the conjugate, including molecular weight, size (diameter), symmetry, shape/rigidity and charge. Usually, a molecular weight of roughly about 66-67 kDa is considered to be a cut-off-value for renal clearance (although this can vary depending on e.g. the diameter and shape of the molecule, i.e. the "apparent size” as determined e.g. by SDS-PAGE).
  • a reduced renal clearance may be established by any suitable assay, e.g. an established in vivo assay.
  • the renal clearance is determined by administering a labelled (e.g. radiolabelled or fluorescence labelled) polypeptide conjugate to a patient and measuring the label activity in urine collected from the patient.
  • the reduced renal clearance is determined relative to the corresponding non- conjugated polypeptide or the corresponding non-conjugated wild-type polypeptide under comparable conditions.
  • function is intended to indicate one or more specific functions of the polypeptide of interest and is generally to be understood qualitatively (i.e. having a similar function as the polypeptide of interest) and not necessarily quantitatively (i.e. the magnitude of the function is not necessarily similar).
  • the specific function of interest will in particular be one or more biological activities, e.g. in vitro or in vivo bioactiv- ity.
  • measurable function and “functional” are intended to indicate that the relevant function (preferably reflecting the intended use) of a conjugate of the invention may be detected when measured by standard methods known in the art, e.g. as in vitro and/or in vivo bioactivity.
  • a measurable function is at least 1%, such as at least 2% or 5%, preferably at least 10%, such as at least 25% or 50%, of that of the non-conjugated polypeptide as determined under comparable conditions, e.g. in the range of 1-1000%, such as 5-500% or 10-200% of the function of the non-conjugated polypeptide.
  • mutant and wild-type are used about a polypeptide which has an amino acid sequence that is identical to one found in nature.
  • the native polypeptide is typically isolated from a naturally occurring source, in particular a mammalian or microbial source, such as a human source, or is produced recombinantly by use of a nucleotide sequence encoding the naturally occurring amino acid sequence.
  • native is intended to encompass allelic variants of the polypeptide in question.
  • a “variant” is a polypeptide which has an amino acid sequence that differs from that of a native polypep- tide in one or more amino acid residues.
  • the variant is typically prepared by modification of a nucleotide sequence encoding the native polypeptide (e.g. to result in substitution, deletion or truncation of one or more amino acid residues of the polypeptide) or by introduction (by addition or insertion) of one or more amino acid residues into the polypeptide) so as to modify the amino acid sequence constituting said native polypeptide.
  • a "fragment” is a part of a parent native or variant polypeptide, typically differing from such parent in one or more C- terminal or N-terminal amino acid residues or both types of such residues. Normally, the variant or fragment has retained at least one of the functions of the corresponding parent polypeptide, although as indicated above, the function of a variant or fragment need not be quantitatively comparable to that of the parent polypeptide.
  • any reference to a polypeptide that is "biologically active in monomeric form" is intended to mean a cytokine, hormone, growth factor or other polypeptide with therapeutic activity that in its native form and in its native environment is mainly found in monomeric form in solution, and where the native monomeric polypeptide is biologically active in vivo.
  • G-CSF polypeptide in this latter category
  • native hG-CSF occurs in vivo as a monomer.
  • Activation of the G-CSF receptor takes place via binding of two G-CSF molecules to a pair of G-CSF receptors, forming a 2:2 complex between the two receptor domains and the ligand, even though the two G-CSF molecules do not form a dimer as such (Aritomi et al., Nature, Vol. 401: 713-717, 14 Oct. 1999).
  • the monomeric polypeptides outlined above can be contrasted to polypeptides that normally occur in vivo in the form of e.g. dimers or trimers, for example with monomeric units bound together by disulfide bonds or hydrogen bonding, and where the formation of such multimers is a prerequisite for receptor binding or other biological activity.
  • Polypeptides in this category can be either homomers, e.g. a homodimer comprising two identical monomers, or heteromers, e.g. a heterodimer comprising two different monomers.
  • the single-chain multimeric polypeptides and conjugates of the inven- tion based on polypeptides that are biologically active in monomeric form is that the single- chain multimeric polypeptides will normally have a reduced clearance and a longer circulation half-life than the corresponding monomeric polypeptides. This is due to the higher molecular weight of the multimeric polypeptide as well as possible attachment of non- polypeptide moieties.
  • the biological activity provided by the multimeric polypeptides and conjugates of the invention is in particular agonist activity, i.e. binding of a polypeptide of the invention to its receptor results in receptor activation, thereby providing a signal initiating a signal transduction cascade in the cell carrying the receptor.
  • Cytokines that in their native form have a monomeric structure in solution and are thus suitable for use in the single-chain polypeptides and conjugates of the invention include interleukins such as interleukin- 1 alpha (IL-l ), interleukin- lbeta (EL-l ⁇ ), interleukin- Ira (IL-lra), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin- 11 (IL-11), inter- leukin-13 (IL-13), interleukin- 15 (E -15), interleukin 17 (IL-17) and interleukin 18 (JL-18); colony stimulating factors such as granulocyte colony stimulating factor (G-CSF) and granu- locyte macrophage colony stimulating factor (GM-CSF); growth factors such as epidermal growth factor
  • EPO erythropoietin
  • human growth hormone EPO
  • the present invention is primarily directed to single-chain multimeric polypeptides based on polypeptides that are biologically active in monomeric form, it is also contemplated that the principles described herein will be applicable to polypeptides of the type that exist as dimers, trimers and other multimers in vivo. In this case, creating e.g. a single-chain dimeric polypeptide based on a polypeptide that normally exists and is active as a dimer in vivo might be of little significance in terms of the molecular weight of the polypeptide itself (with the possible exception of added weight provided by a relatively large linker sequence).
  • FSH follicle stimulating hormone
  • the invention therefore relates to a general method for reducing receptor-mediated clearance of a polypeptide, compared to the relevant wild-type polypeptide, by producing the polypeptide in the form of a single-chain construct comprising two or more monomeric units linked by a peptide bond or peptide linker.
  • This general method is contemplated to be applicable to polypeptides that in their native form are biologically active as monomers as well as to polypeptides that are biologically active as multimers. While the polypeptides used according to the invention may be of any origin, they are normally of mammalian origin, in particular of human origin.
  • the multimeric polypeptides and conjugates of the invention comprise two or more monomeric polypeptide units with similar biological activity, in particular two or more monomeric polypeptide units that have substantially the same biological activity and which may be substantially similar in sequence.
  • similar biological activity refers to the fact that the two or more monomeric units should be of the same type of molecule and have the same type of biological activity or at least be derived from a molecule with the same type of biological activity.
  • the individual monomeric units may in some cases have an identical amino acid sequence, it will be clear that the individual sequences need not be identical and that the level of their biological activity need not be identical.
  • a dimeric polypeptide according to the invention may comprise, e.g., two identical monomers of wild-type G-CSF, a wild-type G-CSF monomer and a variant in which one or more amino acids have been inserted and/or removed relative to the wild-type G-CSF monomer, two G-CSF variants (which may be identical or different from each other), a wild-type G-CSF monomer and a fragment thereof, a G-CSF variant and a fragment of the variant or of the wild-type monomer, etc.
  • trimer for example, it may comprise three identical monomeric units, two identical monomeric units (wild-type or variant) and one unit which is different from the two (e.g. a variant or fragment), or three different units.
  • trimer for example, it may comprise three identical monomeric units, two identical monomeric units (wild-type or variant) and one unit which is different from the two (e.g. a variant or fragment), or three different units.
  • the individual monomers are identical the polypeptide is termed a "homomer”, and when they are different from each other the polypeptide is termed a "heteromer".
  • the monomers used for constructing the multimeric polypeptide may be linked by a peptide bond, or may be connected by a suitable linker peptide.
  • the linker peptide should be of a type (length, amino acid composition, amino acid sequence, etc.) that is adequate to link two (or more) monomers in such a way that they assume a conformation rela- tive to one another so that the resulting multimeric polypeptide has the desired activity.
  • the linker peptide is typically designed to increase the stability of the resulting multimeric polypeptide towards proteolytic degradation, e.g. by use of special amino acid sequences or residues not readily subject to proteolysis.
  • the peptide linker sequence may comprise one or more attachment groups for said non-polypeptide moiety.
  • the linker when the non-polypeptide moiety is an oligosaccharide moiety the linker can contain a sequence that provides an N-glycosylation site.
  • the linker when the non-polypeptide moiety is PEG, the linker can contain e.g. Lys or Cys.
  • the linker peptide will often predominantly include the amino acid residues Gly, Ser, Ala and/or Thr.
  • the linker typically comprises 1-30 amino acid residues, such as a sequence of about 2-20 or 3-15 amino acid residues.
  • the amino acid residues selected for inclusion in the linker peptide should exhibit properties that do not interfere significantly with the activity of the multimeric polypeptide.
  • the linker peptide should on the whole not exhibit a charge which would be inconsistent with the desired activity of the multimeric polypeptide, or interfere with internal folding, or form bonds or other interactions with amino acid residues in one or more of the monomers which would seriously impede the binding of the multimeric polypeptide to the ligand-binding domain of the receptor.
  • linkers for use in the present invention may be designed on the basis of known naturally occurring as well as artificial polypeptide linkers (see, e.g., Hallewell et al. (1989), /. Biol. Chem. 264, 5260-5268; Alfthan et al. (1995), Protein Eng. 8, 725-731; Robinson & Sauer (1996), Biochemistry 35, 109-116; Khandekar et al. (1997), J. Biol. Chem. 272, 32190-32197; Fares et al. (1998), Endocrinology 139, 2459-2464; Smallshaw et al. (1999), Protein Eng. 12, 623-630; US 5,856,456).
  • linkers used for creating single-chain antibodies e.g. a 15mer consisting of three repeats of a Gly-Gly-Gly-Gly-Ser amino acid sequence ((Gly 4 Ser) 3 ), are contemplated to be useful in the present invention.
  • Other linkers that contemplated to be useful in the present invention are GlySerThrSerGly- SerSerGlyLysSerSerGluGlyLysGly, and GlyGlyGlyGlyGlySerGlyGlyGlyGlyAsnSerThrGlyGly- GlySer, the latter being an example of a linker providing a glycosylation site (AsnSerThr).
  • phage display technology as well as selective infective phage technology can be used to diversify and select appropriate linker sequences (Tang et al., J. Biol. Chem. 271, 15682-15686, 1996; Hennecke et al. (1998), Protein Eng. 11, 405-410).
  • Arc repressor phage display has been used to optimize the linker length and composition for increased stability of the single-chain protein (Robinson and Sauer (1998), Proc. Natl. Acad. Sci. USA 95, 5929-5934).
  • Another way of obtaining a suitable linker is by optimizing a simple linker, e.g. ((Gly Ser) n ), through random mutagenesis. It will be clear from the present specification that whatever the nature of the linker, it should be one which is not readily susceptible to cleav- age by e.g. proteases or chemical agents, since cleavage of the multimeric polypeptide to result in two or more monomeric units is not desired in the present context.
  • the multimeric polypeptide conjugate comprises two or more monomeric polypeptide units with the same amino acid sequence, and with at least one non-polypeptide moiety attached to an attachment group thereof.
  • the multimeric polypeptide may comprise two or more wild-type monomeric units linked together so as to obtain a multimeric polypeptide having a sufficiently high molecular weight, i.e. without any monomeric units that differ from the wild-type polypeptide, other than the presence of one or more attached non-polypeptide moieties.
  • the polypeptide may comprise two or more units that are modified, in relation to the relevant wild- type amino acid sequence, by insertion and/or removal of one or more amino acid residues, e.g. by substitution of one or more amino acid residues in the native sequence with a non- native amino acid residue.
  • the multimeric polypeptide comprises two or more monomeric polypeptide units with different amino acid sequences. As indicated above, this can e.g. for the case of a dimer be a wild-type unit and a modified unit or two modified units that are different from each other.
  • a single-chain multimeric polypeptide with non-identical monomeric units provides the advantage that the individual units can be designed to give different desired characteristics to the multimeric polypeptide.
  • the amino acid sequence of one of the monomeric units of a dimeric polypeptide of the invention can be designed for optimal binding to a receptor, while the amino acid sequence of the other monomeric unit can be designed to provide optimal attachment sites for non-polypeptide moieties in order to obtain desired properties of molecular weight, bulk, etc.
  • the monomeric units of the multimeric polypeptide must be biologically active, i.e. capable of binding to the intended target receptor with a sufficient binding affinity to elicit a desired receptor activation. In some cases it may be sufficient that only one of the monomeric units is biologically active, so that the other mono- meric unit(s) has/have a significantly reduced agonist activity or binding affinity or perhaps substantially no activity or binding affinity, although it is generally preferred that both (or all) of the monomeric units are biologically active and are able to bind to and activate the intended receptor.
  • the second monomeric subunit typically has an amino acid sequence homology to the first monomeric subunit of at least about 70%, preferably at least about 80%, more preferably at least about 85%, still more preferably at least about 90%, such as at least about 95%.
  • the degree of homology may conveniently be determined using the CLUSTAL W sequence alignment program referred to above.
  • each monomeric subunit will typically have a length, determined as the number of amino acid residues compared to the number of amino acid residues in the corresponding wild-type polypeptide (e.g. the relevant wild-type human polypeptide) of at least about 50%, preferably at least about 60%, more preferably at least about 70%, still more preferably at least about 80%, such as at least about 90% or 95% of the length of the wild-type polypeptide.
  • the amino acid sequence of the wild-type polypeptide and the amino acid sequence of the monomeric unit of the invention may differ in that at least one and preferably more, e.g. 2-15, amino acid residues comprising an attachment group for a non-polypeptide moiety have been introduced into the monomeric unit, preferably by substitution, compared to the wild-type amino acid sequence.
  • at least one and preferably more, e.g. 2-15, amino acid residues comprising an attachment group for a non-polypeptide moiety have been introduced into the monomeric unit, preferably by substitution, compared to the wild-type amino acid sequence.
  • shielding by non-polypeptide moieties may be achieved in more or different regions of the polypeptide molecule, leading to a lower immune response, and/or the molecular weight, shape, size and/or charge of the conjugate may be optimised.
  • such amino acid residue is introduced in an amino acid located at the surface of the polypeptide, more preferably in a position occupied by an amino acid residue having more than 25%, such as more than 50% or even more than 75% of its side chain exposed at the surface of the molecule.
  • surface-exposed refers to an amino acid residue with a side chain that is at least partially exposed at the surface of the molecule, in particular at least 25% exposed.
  • a method for determining the percentage exposed surface area of side chains of amino acid residues, and thus for identifying suitable positions for modification, based on an analysis of the 3D structure of the polypeptide, is given in the Materials and Methods section below.
  • the position to be modified may be identified on the basis of an analysis of the sequence family of the polypeptide in question.
  • the position to be modified can be one that in one or more members of the family other than the parent polypeptide is occupied by an amino acid residue comprising the rele- vant attachment group (when such amino acid residue is to be introduced) or which in the parent polypeptide, but not in one or more other members of the f mily, is occupied by an amino acid residue comprising the relevant attachment group (when such amino acid residue is to be removed).
  • the distance be- tween amino acid residues located at the surface of the polypeptide is calculated on the basis of the polypeptide' s 3D structure. More specifically, the distance between the CB's of the amino acid residues comprising such attachment groups, or the distance between the functional group (NZ for lysine, CG for aspartic acid, CD for glutamic acid, SG for cysteine) of one and the CB of another amino acid residue comprising an attachment group are deter- mined. In case of glycine, CA is used instead of CB. In polypeptides according to the invention, any of said distances is preferably more than 8A, in particular more than loA, in order to avoid or reduce heterogeneous conjugation.
  • one difference between the amino acid sequence of the wild-type polypeptide and the amino acid sequence of the monomeric unit used herein is that one or preferably more, e.g. 2-15, amino acid residues comprising an attachment group for a non-polypeptide moiety have been removed, preferably by substitution, from the wild- type amino acid sequence.
  • the amino acid residue to be removed is preferably one to which conjugation is disadvantageous, e.g. an amino acid residue located at or near a functional site of the polypeptide (since conjugation at such a site may result in inactivation or reduced activity of the resulting conjugate due to impaired receptor recognition).
  • the term "functional site” is intended to indicate one or more amino acid residues which is/are essential for or otherwise involved in the function or performance of the polypeptide, in particular receptor binding and/or activation.
  • the functional site may be determined by methods known in the art and is preferably identified by analysis of a structure of the polypeptide complexed to a relevant receptor.
  • more than one amino acid resi- due of at least one monomeric unit is altered, e.g. the alteration embraces removal as well as introduction of amino acid residues comprising an attachment group for the non-polypeptide moiety of choice.
  • the amino acid sequence of the monomeric polypeptide unit may differ from the relevant wild-type amino acid sequence in that a) at least one amino acid residue comprising an attachment group for the non-polypeptide moi- ety and present in the wild-type amino acid sequence has been removed, preferably by substitution, and b) at least one amino acid residue comprising an attachment group for the non- polypeptide moiety has been introduced into the amino acid sequence, preferably by substitution.
  • This embodiment is considered of particular interest in that it is possible to specifically design the polypeptide so as to obtain an optimal conjugation to the non-polypeptide moiety of choice. For instance, by introducing and removing selected amino acid residues, e.g. as exemplified below for G-CSF, it is possible to ensure an optimal distribution of attachment groups for the non-polypeptide moiety of choice, which gives rise to a conjugate in which the non-polypeptide moieties are placed so as to effectively shield epitopes and other surface parts of the polypeptide without substantially impairing the function of the polypep- tide.
  • selected amino acid residues e.g. as exemplified below for G-CSF
  • one of the monomeric units comprises either a wild-type sequence or a variant sequence modified such that one or more attachment sites for a non-polypeptide moiety have been removed as compared to the wild-type, thereby avoiding attachment of undesired non-polypeptide moieties to this monomeric unit (although it may, if desired, maintain any naturally occurring glycosylation sites so as to allow glycosylation corresponding to the native polypeptide), while the other monomeric unit comprises a sequence with one or more attached non-polypeptide moieties.
  • the latter monomeric unit may have an amino acid sequence corresponding to that of the wild-type, but with one or more polymer moieties attached thereto, e.g. PEG moieties, or it may be a variant with introduced and/or removed attachment groups for polymer and/or oligosaccharide moieties.
  • the advantage of this approach is that the re- suiting multimeric polypeptide comprises a monomeric unit corresponding in sequence and possible glycosylation to the native polypeptide together with a monomeric unit modified with one or more attachment groups, and possibly with additional amino acid modifications, so as to give the overall monomeric polypeptide the desired properties in terms of biological activity, molecular weight, half-life, epitope shielding, etc.
  • the polypeptide may comprise other substitutions or glycosylations which are not related to introduction and/or removal of amino acid residues comprising an attachment group for the non- polypeptide moiety.
  • the total number of amino acid residues to be altered in accordance with the present invention will typically not exceed 15.
  • the exact number of amino acid residues and the type of amino acid residues to be introduced and/or removed depend, i.a., on the desired nature and degree of conjugation (e.g. the identity of the non-polypeptide moiety, how many non-polypeptide moieties it is desirable or possible to conjugate to the polypeptide, where in the polypeptide conjugation should be performed or avoided, etc.).
  • the polypeptide part of the conjugate of the invention or the polypeptide of the invention comprises an amino acid sequence which differs in 1-15 amino acid residues from the native amino acid sequence such as in 1-8 or 2-8 amino acid residues, e.g. in 1-5 or 2-5 amino acid residues.
  • the polypeptide part of the conjugate or the polypeptide of the invention comprises an amino acid sequence which differs from the native amino acid sequence in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues.
  • the conjugate of the present invention will normally have one or more improved properties as compared to the native polypeptide, including increased functional in vivo half- life, increased serum half -life, reduced clearance, reduced immunogenicity and/or increased bioavailability. Consequently, medical treatment with a conjugate of the invention offers a number of advantages over the currently available compounds, including longer duration between injections and fewer side effects. As explained above, the increased functional in vivo half-life is normally obtained as a consequence of the conjugate of the invention having a reduced susceptibility to renal and/or receptor-mediated clearance as compared to the native monomeric polypeptide, in part as a result of an increased molecular weight.
  • the actual molecular weight does not necessarily have to be above any certain limit, e.g. 60 or 65 kDa, in order to achieve reduced renal clearance, since renal clearance depends not only on the molecular weight as such, but also on e.g. on the three-dimensional structure and bulk of the conjugate.
  • the "apparent size" of the conjugate e.g. as determined by SDS-PAGE, is sufficiently high, e.g. at least about 60 or 65 kDa, such as at least about 66 or 67 kDa.
  • Polymer molecules such as PEG have been found to be particularly useful for adjusting the molecular weight of the conjugate and for providing a sufficiently high apparent size.
  • each monomeric polypeptide unit will often have a molecular weight (exclusive of any polymer moiety bound to said unit) of less than about 34 kDa, such as less than about 30 kDa.
  • the multimeric polypeptide conjugate of the invention thus comprises at least one non-polypeptide moiety bound to an attachment group of at least one of the monomeric polypeptide units, such that the apparent size of the multimeric polypeptide conjugate is at least about 60 kDa, such as at least about 65 kDa, e.g. at least about 67 kDa.
  • RMC receptor-mediated clearance
  • the clearance is due to internalisation of the receptor-bound polypeptide with subsequent lysosomal degradation.
  • Reduced RMC may be achieved by designing the conjugate so as to be able to bind and activate a sufficient number of receptors to obtain optimal in vivo biological response and avoid activation of more receptors than required for obtaining such response. This may be reflected in reduced in vitro bioactivity and/or increased off-rate.
  • reduced in vitro bioactivity reflects reduced efficacy/efficiency and/or reduced potency and may be determined by any suitable method for determining any of these properties.
  • in vitro bioactivity may be determined in a luciferase based assay (see Materials and Methods).
  • a relatively low in vitro bioactivity compared to the bioactivity of hG-CSF (SEQ ID NO:l), is advantageous in terms of both a long plasma half -life and a high degree of stimulation of neutrophils. This is explained in further detail below.
  • a preferred single-chain polypeptide conjugate of the invention is one comprising two or more subunits of a G-CSF polypeptide, e.g. two, three or four subunits, although normally the multimeric polypeptide will contain two subunits.
  • these may be two monomers each comprising the amino acid sequence of hG-CSF as shown in SEQ ID NO: 1, a monomer having the sequence of hG-CSF together with a monomer having an amino acid sequence that is altered relative to hG-CSR, or two monomers with altered amino acid sequences relative to hG-CSF.
  • One embodiment of this aspect of the invention thus relates to a single-chain multimeric polypeptide having G-CSF activity, comprising at least two monomeric units inde- pendently selected from (a) hG-CSF with the amino acid sequence shown in SEQ ID NO: 1 and (b) variants of hG-CSF, said monomeric units being linked via a peptide bond or a peptide linker, wherein the polypeptide has at least one non-polypeptide moiety covalently bound to an attachment group of the polypeptide.
  • Another embodiment of this aspect of the invention relates to a single-chain mul- timeric polypeptide having G-CSF activity, comprising at least two monomeric units independently selected from (a) hG-CSF with the amino acid sequence shown in SEQ ID NO:l and (b) variants of hG-CSF, said monomeric units being linked via a peptide bond or a peptide linker, wherein the polypeptide has at least one non-polypeptide moiety covalently bound to an attachment group of the polypeptide and exhibits an in vitro bioactivity in the range of about 2-30% of the bioactivity of non-conjugated hG-CSF as determined by the luciferase assay described herein.
  • the invention relates to a single-chain multimeric polypeptide having G-CSF activity, comprising at least two monomeric units independently selected from (a) hG-CSF with the amino acid sequence shown in SEQ ID NO:l and (b) variants of hG-CSF, said monomeric units being linked via a peptide bond or a peptide linker, the polypeptide comprising at least one covalently bound polymer molecule selected from the group consisting of linear and branched polyalkylene oxides.
  • the invention relates to a single-chain multimeric polypeptide having G-CSF activity, comprising at least two monomeric units independently selected from (a) hG-CSF with the amino acid sequence shown in SEQ ID NO:l and (b) variants of hG-CSF, said monomeric units being linked via a peptide bond or a peptide linker, the polypeptide comprising at least one covalently bound polyethylene glycol molecule.
  • G-CSF refers to polypeptides comprising the amino acid sequence of wild-type human G-CSF as set forth in SEQ ID NO:l as well as variants thereof with one or more changes in the form of substitutions, additions/insertions or deletions compared to SEQ ID NO:l.
  • G-CSF variants are disclosed in detail below.
  • the amino acid residue modifications in G-CSF variant monomeric units may in particular be selected from the group consisting of introduction of a lysine, cysteine, aspartic acid, glutamic acid or histidine residue, and removal of a lysine, cysteine, aspartic acid, glutamic acid or histidine residue.
  • at least one of the mono- mers of the single-chain multimeric G-CSF polypeptide of this aspect of the invention may comprise at least one amino acid residue modification selected from the group consisting of introduction of an N- or O-glycosylation site, and removal of an O-glycosylation site.
  • the single-chain multimeric G-CSF polypeptide comprises at least two G-CSF polypeptide monomers linked via a peptide bond or a peptide linker, wherein at least one of said monomers is a variant of wild-type human G-CSF comprising at least one introduced attachment site for a polymer moiety.
  • the single-chain multimeric G-CSF polypeptide comprises at least two G-CSF polypeptide monomers linked via a peptide bond or a peptide linker, wherein at least one of said monomers is a variant of wild-type human G-CSF wherein at least one attachment site for a non-polypeptide moiety has been introduced in a position that in wild-type human G-CSF is occupied by a surface-exposed amino acid residue.
  • the single-chain multimeric G-CSF polypeptide comprises at least two G-CSF polypeptide monomers linked via a peptide linker, wherein the peptide linker comprises at least one amino acid residue comprising an attachment group for a non-polypeptide moiety.
  • G-CSF G-CSF
  • Recombinant human G-CSF is generally used for treating various forms of leukopenia/neutropenia, i.e. a reduced white blood cell count that arises e.g. as a result of chemotherapy. Since leukopenia is a serious side effect of chemotherapy that increases the risk of infection and can reduce the effectiveness of chemotherapy, it is important to be able to reduce the time period during which patients are subject to leukopenia.
  • rhG-CSF Commercial preparations of rhG-CSF are available under the names filgrastim (Gran® and Neupogen®), lenograstim (Neutrogin® and Granocyte®) and nartograstim (Neu-up®).
  • Gran® and Neupogen® are non-glycosylated and produced in recombinant E. coli cells.
  • Neutrogin® and Granocyte® are glycosylated and produced in recombinant CHO cells and Neu-up® is non-glycosylated with five amino acids substituted at the N-terminal region of intact rhG-CSF produced in recombinant E. coli cells.
  • the commercially available rhG-CSF has a short-term pharmacological effect and must often be administered more than once per day for the duration of the leukopenic state.
  • a molecule with a longer circulation half-life would decrease the number of administrations necessary to alleviate the leukopenia and prevent consequent infections.
  • the in vitro bioactivity of a multimeric G- CSF conjugate of the invention is in the range of about 1-30%, preferably about 2-30%, of the bioactivity of non-conjugated hG-CSF as determined by the luciferase assay described herein.
  • the in vitro bioactivity of such conjugates is thus preferably reduced by at least about 70%, such as by at least about 75%, e.g. by at least about 80% or 85%, as compared to the in vitro bioactivity of hG-CSF, determined under comparable conditions.
  • the conjugate may have an in vitro bioactivity that is as small as about 1%, typically at least about 2%, such as at least about 3%, 4% or 5%, of that of the corresponding non-conjugated hG-CSF polypeptide.
  • the in vitro bioactivity may be in the range of about 2-30% of that of the reference polypeptide, e.g. about 3-25% or 4-20%, determined under comparable conditions.
  • the bioactivity should be at least about 1-2% of that of hG-CSF and preferably slightly higher as given above.
  • a single-chain multimeric G-CSF conjugate is in the form of a dimer with either two wild-type monomeric units or with one or possibly two units which are variants of the wild-type human G-CSF (hG-CSF), and preferably attached to one or more PEG moieties.
  • the apparent size (also referred to as the "apparent molecular weight” or "apparent mass”) of the polypeptide conjugates of the invention, or at least a majority of such conjugates is at least about 50 kDa, preferably at least about 55 kDa, more preferably at least about 60 kDa, e.g. at least about 66 kDa. This is believed to be due to the fact that renal clearance is substantially eliminated for conjugates having a sufficiently large apparent size.
  • the "apparent size" of a G- CSF conjugate or polypeptide is determined by SDS-PAGE as described in the examples section below.
  • the apparent size in kDa of a conjugate or polypeptide is not necessarily the same as the actual molecular weight of the conjugate or polypeptide. Rather, the apparent size is a reflection of both the actual molecular weight and the overall bulk. Since, in most cases, attachment of one or more PEG groups or other non-polypeptide moieties will result in a relatively large increase of the bulk of the polypeptide to which such moieties are attached, the polypeptide conjugates of the invention will normally have an apparent size that exceeds the actual molecular weight of the conjugate. Therefore, in connection with renal clearance, a conjugate of the invention can easily exhibit properties char- acteristic of a polypeptide with a molecular weight above e.g. 50 kDa (corresponding to the apparent size) but have an actual molecular weight below 50 kDa.
  • the multimeric G-CSF conjugates of the invention have both an apparent size of at least about 50 kDa and a reduced in vitro bioactivity (reduced receptor binding affinity) compared to hG-CSF as explained above. It has been found that such conjugates have both a low renal clearance as a result of the large apparent size and a low receptor-mediated clearance as a result of the low in vitro bioactivity (low receptor binding affinity). The overall result is excellent performance in terms of effective stimulation of neutrophils together with a significantly increased in vivo half-life and thus a long duration of action that provides important clinical advantages.
  • the conjugate of the invention is one wherein the amino acid residue comprising an attachment group for the non-polypeptide moiety is a lysine residue and the non-polypeptide moiety is any molecule which has lysine as an attachment group.
  • the non-polypeptide moiety may be a polymer molecule, in particular any of the molecules mentioned in the section entitled "Conjugation to a polymer molecule", and preferably selected from the group consisting of linear or branched polyethylene glycol or another polyalkylene oxide.
  • the polymer molecule is a PEG such as mPEG-SPA (Shearwater Corp.) or oxycarbonyl-oxy-N-dicarboxyimide PEG (US 5,122,614).
  • the conjugate of the invention is one which comprises a non-polypeptide moiety having lysine as attachment group and a polypeptide comprising an amino acid sequence that differs from the native sequence in that at least one ly- sine residue has been introduced. Residues are in particular introduced such that they have more than 50% of the side chain surface exposed.
  • one or both of the monomeric units may thus have an amino acid sequence that differs from the amino acid sequence shown in SEQ ID NO:l in at least one substitution selected from the group consisting of T1K, P2K, L3K, G4K, P5K, A6K, S7K, S8K, L9K, P10K, Q11K, S12K, F13K, L14K, L15K, E19K, Q20K, V21K, R22K, Q25K, G26K, D27K, A29K, A30K, E33K, A37K, T38K, Y39K, L41K, H43K, P44K, E45K, E46K, V48K, L49K, L50K, H52K, S53K, L54K, I56K, P57K, P60K, L61K, S62K, S63K, P65K, S66K, Q67K, A68K, L69K
  • Examples of preferred amino acid substitutions include one or more of Q70K, Q90K, T105K, Q120K, T133K, R146K, R147K, S159K, R166K and R169K.
  • the polypeptide conjugate of the invention having introduced and/or removed at least one lysine is preferably in vivo glycosylated, e.g. using naturally-occurring glycosylation sites present in the polypeptide.
  • the conjugate is one wherein the amino acid sequence of the polypeptide differs from that of the native polypeptide in that at least one N-glycosylation site has been introduced and/or removed.
  • Such introduced/removed sites may any of those described in the section entitled "Conjugate of the invention wherein the non-polypeptide moiety is an oligosaccharide moiety".
  • the conjugate according to this embodiment comprises at least one monomeric polypeptide unit comprising an amino acid sequence that differs from the native amino acid sequence in the removal of at least one lysine residue, in particular a lysine residue selected from those having more than 25% of their side chains surface exposed, preferably selected from those having more than 50% of their side chain surface exposed.
  • hG-CSF contains four lysine residues, of which K16 is located in the receptor- binding domain and the others are located in positions 23, 34 and 40, respectively, all relatively close to the receptor-binding domain.
  • one or both of the G-CSF monomeric units may comprise an amino acid sequence which, in addition to or instead of having one or more of the substitutions to lysine listed above, is modified in relation to hG-CSF by removal of at least one of the amino acid residues selected from the group consisting of K16, K23, K34 and K40, in particular at least K16, the removal preferably being achieved by substitution by any other amino acid residue, in particular an arginine or a glutamine residue.
  • One or both of the subunits may thus have a single lysine residue removed, or all of the four native lysine residues removed, or two or three lysine residues removed, i.e.
  • the single-chain G-CSF polypeptide according to this aspect of the invention preferably comprises at least one monomeric unit having at least one of the substitutions se- lected from the group consisting of K16R, K16Q, K23R, K23Q, K34R, K34Q, K40R and K40Q, more preferably at least one of the substitutions K16R and K23R, whereby conjugation of these residues can be avoided.
  • the polypeptide comprises at least one substitution selected from the group consisting of K16R+K23R, K16R+K34R, K16R+K40R, K23R+K34R, K23R+K40R, K34R+K40R, K16R+K23R+K34R, K16R+K23R+K40R, K23R+K34R+K40R and K16R+K34R+K40R.
  • substitutions are likely to give rise to the least structural difference.
  • both of the monomeric units of the single-chain G-CSF polypeptide are modified by removal of one or more lysines as described above.
  • the lysines that are removed may be the same in the two subunits or they may differ. Jf desired, removal of lysines in this embodiment may be accompanied by introduction of one or more lysines in one or both of the subunits, although it has been found that surprisingly advantageous results are obtained simply by removing one or more lysines from the two subunits, without any introduction of lysines, when lysine PEGylation is used.
  • Hi Introduction and removal of lysine residues
  • the conjugate of the invention comprises at least one introduced lysine residue and at least one removed lysine residue.
  • Conjugate of the invention having a non-lysine residue as an attachment group
  • amino acid residues comprising other attachment groups may be introduced into and/or removed from the native monomeric polypeptide using the same approach as that illustrated above with lysine residues.
  • one or more amino acid residues comprising an acid group glutamic acid or aspartic acid
  • asparagine asparagine
  • histidine asparagine
  • tyrosine cysteine
  • cysteine may be introduced into positions which are occupied by amino acid residues having surface exposed side chains, or removed (preferably by substitution by any other amino acid residue).
  • Such modified polypeptides may further be in vivo glycosylated.
  • cysteine attachment groups may be provided by means of an amino acid sequence that differs, in at least one monomeric unit, from the amino acid sequence of hG-CSF shown in SEQ ID NO:l in at least one substitution selected from the group consisting of TIC, P2C, L3C, G4C, P5C, A6C, S7C, S8C, L9C, P10C, Q11C, S12C, F13C, L14C, L15C, E19C, Q20C, V21C, R22C, Q25C, G26C, D27C, A29C, A30C, E33C, A37C, T38C, Y39C, L41C, H43C, P44C, E45C, E46C, V48C, L49C, L50C, H52C, S53C, L54C, I56C, P57C, P60C, L61C, S62C,
  • the receptor-binding domain of hG-CSF contains a cysteine residue in position 17 which does not take part in a cystine and which may therefore advantageously be removed in order to avoid conjugate of a non-polypeptide moiety to said cysteine.
  • C17 may be substituted by any other amino acid residue, it is in particular substituted by a serine residue. Examples of preferred substitutions according to this aspect of the invention include R146C, R147C, R166C and R169C.
  • a single-chain G-CSF conjugate according to the invention may also have one or more non-polypeptide moieties bound to an acid group or to the C-terminal amino acid resi- due, in particular to an aspartic acid or glutamic acid residue.
  • the amino acid sequence of at least one of the monomeric units may differ from the amino acid sequence shown in SEQ ID NO:l in at least one substitution selected from the group consisting of T1D, P2D, L3D, G4D, P5D, A6D, S7D, S8D, L9D, P10D, Q11D, S12D, F13D, L14D, L15D, K16D, Q20D, V21D, R22D, K23D, Q25D, G26D, A29D, A30D, K34D, A37D, T38D, Y39D, K40D, L41D, H43D, P44D, V48D, L49D, L50D, H52D, S53D, L54D, I56D, P57D, P60D, L61D, S62D, S63D, P65D, S66D, Q67D, A68D, L69D, Q70D, L71D, A72D, G73
  • a G-CSF monomeric unit may by modified in relation to hG-CSF as shown in SEQ ID NO:l by removal, preferably by substitution, of at least one of the amino acid resi- dues selected from the group consisting of D27, D104, D109, D112, E19, E33, E45, E46, E93, E98, E122, E123 and E163.
  • the substitution may be by any other amino acid residue, in particular by an asparagine or a glutamine residue, whereby conjugation of these residues to a non-polypeptide moiety can be avoided.
  • the invention relates to a conjugate comprising a glycosylated polypeptide in which at least one non-naturally occurring glycosylation site has been introduced into the amino acid sequence.
  • a suitable N-glycosylation site may be introduced by introducing, preferably by substitution, an asparagine residue in a position occupied by an amino acid residue having more than 25% of its side chain exposed at the surface of the polypeptide, which position does not have a proline residue located in position +1 or +3 therefrom. If the amino acid residue located in position +2 is a serine or threonine, no further amino acid substitution is required. However, if this position is occupied by a different amino acid residue, a serine or threonine residue needs to be introduced.
  • one or more non-naturally occurring glycosylation sites may be introduced into at least one monomeric unit relative to the amino acid sequence of hG-CSF by way of at least one substitution selected from the group consisting of L3N+P5S/T, P5N, A6N, S8N+P10S/T, P10N, Ql 1N+F13S/T, S 12N+L14S/T, F13N+L15S/T, L14N+K16S/T, K16N+L18S/T, E19N+V21S/T, Q20N+R22S/T, V21N+K23S/T, R22N+I24S/T, K23N+Q25S/T, Q25N+D27S/T, G26N+G28S/T, D27N+A29S/T, A29N+L31S/T, A30N+Q32S/T, E33N+L35S
  • S/T indicates an S or a T residue, preferably a T residue.
  • the conjugate according to this aspect may comprise at least one monomeric unit comprising an amino acid sequence that differs from that shown in SEQ ID NO :1 in at least one substitution selected from the group consisting of P5N, A6N, PI ON, P60N, L61N, L78N, Fl 13N and E162N, in particular from the group consisting of P5N, A6N, P10N, P60N, L61N, F113N and E162N, such as from the group consisting of P60N, L61N, F113N and E162N.
  • the conjugate according to this aspect may comprise at least one monomeric unit comprising an amino acid sequence that differs from that shown in SEQ ID NO: 1 in at least one substitution selected from the group consisting of D27N+A29S, D27N+A29T, D104N+L106S, D104N+L106T, D109N+A111S, D109N+A111T, D112N+A114S and D112N+A114T, more preferably from the group consisting of D27N+A29S, D27N+A29T, D104N+L106S, D104N+L106T, Dl 12N+A114S and D112N+A114T, such as from the group consisting of D27N+A29S, D27N+A29T, D104N+L106S and D104N+L106T.
  • the polypeptide may have an amino acid sequence in which at least one naturally occurring N-glycosylation site has been removed.
  • the amino acid sequence of a polypeptide having at least one of the above mentioned N-glycosylation site modifications may differ from the native sequence in that at least one lysine residue has been removed as identified above in the section entitled "Removal of lysine residues".
  • the polypeptide in order to prepare a conjugate according to this aspect of the invention, the polypeptide must be expressed in a glycosylating host cell capable of attaching oligosaccharide moieties at the glycosylation sites or alternatively subjected to in vitro glycosylation.
  • glycosylating host cells are given in the section below entitled "Coupling to an oligosaccharide moiety".
  • the conjugate according to the aspect of the invention described in the present section may contain additional non-polypeptide moieties, in particular a polymer molecule conjugated to one or more, optionally introduced attachment groups present in the polypeptide part of the conjugate.
  • the non-polypeptide moiety of the conjugate of the invention is preferably selected from the group consisting of a polymer molecule, a lipophilic compound, an oligosaccharide moiety (e.g. by way of in vivo glycosylation) and an organic derivatizing agent. All of these moieties may confer desirable properties to the polypeptide part of the conjugate, in particular an increased functional in vivo half-life and/or an increased serum half -life.
  • the polypeptide part of the conjugate is normally conjugated to only one type of non-polypeptide moiety, but it may also be conjugated to two or more different types of non-polypeptide moieties, e.g.
  • the polypeptide and the lipophilic compound may be conjugated to each other either directly or by use of a linker.
  • the lipophilic compound may be a natural compound such as a saturated or unsaturated fatty acid, a fatty acid diketone, a terpene, a prostaglandin, a vitamin, a carotenoid or steroid, or a synthetic compound such as a carbon acid, an alcohol, an amine or sulphonic acid with one or more alkyl, aryl, alkenyl or other multiple unsatu- rated compounds.
  • the conjugation between the polypeptide and the lipophilic compound, optionally through a linker may be done according to methods known in the art, e.g. as de- scribed by Bodanszky in Peptide Synthesis, John Wiley, New York, 1976 and in WO 96/12505.
  • the polymer molecule to be coupled to the polypeptide may be any suitable polymer molecule, such as a natural or synthetic homo-polymer or hetero-polymer, typically with a molecular weight in the range of 300-100,000 Da, such as 300-20,000 Da, more preferably in the range of 500-10,000 Da, such as in the range of 1000-5000 Da.
  • suitable polymer molecule such as a natural or synthetic homo-polymer or hetero-polymer, typically with a molecular weight in the range of 300-100,000 Da, such as 300-20,000 Da, more preferably in the range of 500-10,000 Da, such as in the range of 1000-5000 Da.
  • homo-polymers include a polyol (i.e. poly-OH), a polyamine (i.e. poly-NH 2 ) and a polycar- boxylic acid (i.e. poly-COOH).
  • a hetero-polymer is a polymer which comprises different coupling groups, such as a hydroxyl group and an amine
  • suitable polymer molecules include polymer molecules selected from the group consisting of polyalkylene oxide (PAO), including polyalkylene glycol (PAG), such as polyethylene glycol (PEG) and polypropylene glycol (PPG), branched PEGs, poly- vinyl alcohol (PNA), poly-carboxylate, poly-(vinylpyrolidone), polyethylene-co-maleic acid anhydride, polystyrene-co-maleic acid anhydride, dextran, including carboxymethyl- dextran, or any other biopolymer suitable for reducing immunogenicity and/or increasing functional in vivo half -life and/or serum half-life.
  • PEO polyalkylene oxide
  • PAG polyalkylene glycol
  • PEG polyethylene glycol
  • PPG polypropylene glycol
  • PNA poly- vinyl alcohol
  • PNA poly-carboxylate
  • poly-(vinylpyrolidone) polyethylene-co-maleic acid anhydride
  • PEG is the preferred polymer molecule, since it has only few reactive groups capable of cross-linking compared to e.g. polysaccharides such as dextran.
  • mono- functional PEG e.g. methoxypolyethylene glycol (mPEG)
  • mPEG methoxypolyethylene glycol
  • the hydroxyl end groups of the polymer molecule must be provided in activated form, i.e. with reactive functional groups.
  • Suitable activated polymer molecules are commercially available, e.g. from Shearwater Corporation, Huntsville, AL, USA.
  • the polymer molecules can be activated by conventional methods known in the art, e.g. as disclosed in WO 90/13540. Specific examples of activated linear or branched polymer molecules for use in the present invention are described in the Shearwater Corp. 2001 Catalog (Polyethylene Glycol and Derivatives for Biomedical Applications, incorporated herein by reference).
  • activated PEG polymers include the following linear PEGs: NHS-PEG (e.g. SPA-PEG, SSPA-PEG, SBA-PEG, SS-PEG, SSA-PEG, SC-PEG, SG-PEG, and SCM- PEG), and NOR-PEG), BTC-PEG, EPOX-PEG, NCO-PEG, NPC-PEG, CDI-PEG, ALD- PEG, TRES-PEG, NS-PEG, IODO-PEG, and MAL-PEG, and branched PEGs such as PEG2- ⁇ HS and those disclosed in US 5,932,462 and US 5,643,575, both of which are incorporated herein by reference.
  • linear PEG e.g. SPA-PEG, SSPA-PEG, SBA-PEG, SS-PEG, SSA-PEG, SC-PEG, SG-PEG, and SCM- PEG
  • BTC-PEG e.g. SPA
  • the activation method and/or conjugation chemistry to be used depends on the attachment group(s) of the polypeptide (examples of which are given further above), as well as the functional groups of the polymer (e.g. amine, hydroxyl, carboxyl, aldehyde, sulfydryl, succinimidyl, maleimide, vinysulfone or haloace- tate).
  • the PEGylation may be directed towards conjugation to all available attachment groups on the polypeptide (i.e. such attachment groups that are exposed at the surface of the polypeptide) or may be directed towards one or more specific attachment groups, e.g. the N- terminal amino group (US 5,985,265).
  • the conjugation may be achieved in one step or in a stepwise manner (e.g. as described in WO 99/55377).
  • the PEGylation is designed so as to produce the optimal molecule with respect to the number of PEG molecules attached, the size and form of such molecules (e.g. whether they are linear or branched), and the attachment site(s) in the polypeptide.
  • the molecular weight of the polymer to be used may e.g. be chosen on the basis of the desired effect to be achieved. For instance, if the primary purpose of the conjugation is to achieve a conjugate having a high molecular weight (e.g. to reduce renal clearance) it is usually desirable to conjugate as few high Mw polymer molecules as possible to obtain the desired molecular weight.
  • a high degree of epitope shielding when a high degree of epitope shielding is desirable this may be obtained by use of a sufficiently high number of low molecular weight polymer molecules (e.g. with a molecular weight of about 5000 Da) to effectively shield all or most epitopes of the polypeptide. For instance, 2-8, such as 3-6 such polymers may be used.
  • the polymer molecule which may be linear or branched, has a high molecular weight, e.g. about 20 kDa.
  • the polymer conjugation is performed under conditions aimed at reacting most or substantially all available polymer attachment groups with polymer molecules, in particular by using a molar excess of the non-polypeptide moiety relative to the polypeptide.
  • the molar ratio of activated polymer molecules to polypeptide is at least about 5:1 and up to about 1000:1, e.g. in the range of from about 10:1 to about 200:1, in order to ob- tain optimal reaction.
  • linker it is also contemplated according to the invention to couple the polymer molecules to the polypeptide through a linker.
  • Suitable linkers are well known to the skilled person.
  • a preferred example is cyanuric chloride (Abuchowski et al., (1977), J. Biol. Chem., 252, 3578-3581; US 4,179,337; Shafer et al., (1986), J. Polym. Sci. Polym. Chem., 24, 375-378).
  • residual activated polymer molecules are blocked according to methods known in the art, e.g. by addition of primary amine to the reaction mixture, and the resulting inactivated polymer molecules are removed by a suitable method.
  • the polypeptide conjugate of the invention is one which comprises a single PEG molecule attached to the N-terminal of the polypeptide and no other PEG molecules, in particular a linear or branched PEG molecule with a molecular weight of at least about 20 kDa.
  • the polypeptide according to this embodiment may further comprise one or more oligosaccharide moieties attached to an N-linked or O-linked glycosylation site of the polypeptide or carbohydrate moieties attached by in vitro glycosylation.
  • the polypeptide conjugate of the invention comprises a PEG molecule attached to most or substantially all of the lysine residues in the polypeptide available for PEGylation, in particular a linear or branched PEG molecule, wherein each PEG e.g. has a molecular weight of about 5 kDa.
  • the polypeptide conjugate of the invention comprises a
  • PEG molecule attached to most or substantially all of the lysine residues in the polypeptide available for PEGylation, and in addition to the N-terminal amino acid residue of the polypeptide.
  • Covalent in vitro coupling of carbohydrate moiety glycosides (such as dextran) to amino acid residues of the polypeptide may also be used, e.g. as described in WO 87/05330 and in Aplin et al., CRC Crit. Rev. Biochem., pp. 259-306, 1981.
  • the in vitro coupling of carbohydrate moieties or PEG to protein- and peptide-bound Gin residues can be carried out by transglutaminases (TGases).
  • Transglutaminases catalyse the transfer of donor amine groups to protein- and peptide-bound Gin residues in a so-called cross-linking reaction.
  • the donor-amine groups can be protein- or peptide-bound such as the ⁇ -amino group in Lys- residues or can be part of a small or large organic molecule.
  • An example of a small organic molecule functioning as amino donor in TGase-catalysed cross-linking is putrescine (1,4- diaminobutane).
  • An example of a larger organic molecule functioning as amino donor in TGase-catalysed cross-linking is an amine-containing PEG (Sato et al., Biochemistry 35, 13072-13080).
  • TGases in general, are highly specific enzymes, and not every Gin residue exposed on the surface of a protein is accessible to TGase-catalysed cross-linking to amino- containing substances. On the contrary, only a few Gin residues function naturally as TGase substrates, but the exact parameters governing which Gin residues are good TGase sub- strates remain unknown. Thus, in order to render a protein susceptible to TGase-catalysed cross-linking reactions it is often a prerequisite at convenient positions to add stretches of amino acid sequence known to function well as TGase substrates. Several amino acid sequences are known to be or to contain excellent natural TGase substrates e.g. substance P, elafin, fibrinogen, fibronectin, 2 -plasmin inhibitor, -caseins, and ⁇ -caseins.
  • the conjugation to an oligosaccharide moiety normally takes place by in vivo glycosylation effected by a glycosylating eucaryotic expression host.
  • the expression host cell may be selected from fungal (filamentous fungal or yeast), insect or animal cells or from transgenic plant cells.
  • the host cell is a mammalian cell, such as a CHO cell, a BHK or a HEK cell, e.g. HEK 293, an insect cell, such as an SF9 cell, or a yeast cell, e.g. Saccharomyces cerevisiae or Pichia pastoris, or any of the host cells mentioned herein- after.
  • glycosylation may alternatively be performed in vitro by a method known per se in the art.
  • Covalent modification of the polypeptide may be performed by reacting one or more attachment groups of the polypeptide with an organic derivatizing agent.
  • organic derivatizing agent Suitable derivatizing agents and methods are well known in the art. For example, cysteinyl residues most commonly are reacted with -haloacetates (and corresponding amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives.
  • Cysteinyl residues also are derivatized by reaction with bromotrifluoroacetone, -bromo- ⁇ -(4- imidozoyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4- nitrophenol, or chloro-7-nitrobenzo-2-oxa-l,3-diazole.
  • Histidyl residues are derivatized by reaction with diethylpyrocarbonateat, pH 5.5-7.0, because this agent is relatively specific for the histidyl side chain.
  • Para-bromophenacyl bromide is also useful.
  • the reaction is prefera- bly performed in 0.1 M sodium cacodylate at pH 6.0. Lysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the effect of reversing the charge of the lysinyl residues.
  • Suitable reagents for derivatizing ⁇ -amino-containing residues include imidoesters such as methyl picolinimi- date, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O- methylisourea, 2,4-pentanedione and transaminase-catalyzed reaction with glyoxylate.
  • Ar- ginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione and ninhydrin.
  • Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine guanidino group.
  • the polypeptide is expressed as a fusion protein with a tag, i.e. an amino acid sequence or peptide stretch made up of typically 1-30, such as 1-20 amino acid residues.
  • a tag i.e. an amino acid sequence or peptide stretch made up of typically 1-30, such as 1-20 amino acid residues.
  • the tag is a convenient tool for achieving conjugation between the tagged polypeptide and the non-polypeptide moiety.
  • the tag may be used for achieving conjugation in microtiter plates or other carriers, such as paramagnetic beads, to which the tagged polypeptide can be immobilised via the tag.
  • the conjugation to the tagged polypeptide in e.g.
  • microtiter plates has the advantage that the tagged polypeptide can be immobilised in the microtiter plates directly from the culture broth (in principle without any purification) and subjected to conjugation. Thereby, the total number of process steps (from expression to conjugation) can be reduced.
  • the tag may function as a spacer molecule ensuring an improved accessibility to the immobilised polypeptide to be conjugated.
  • the conjugation using a tagged polypeptide may be to any of the non-polypeptide moieties disclosed herein, e.g. to a polymer molecule such as PEG.
  • the identity of the specific tag to be used is not critical as long as the tag is capable of being expressed with the polypeptide and is capable of being immobilised on a suitable surface or carrier material.
  • suitable tags are commercially available, e.g. from Unizyme Laboratories, Denmark.
  • the tag may consist of any of the following sequences (SEQ ID NOS: 9-13, respectively):
  • EQKLI SEEDL (a C-terminal tag described in Mol. Cell. Biol. 5:3610-16, 1985)
  • D YKDDDDK (a C- or N-terminal tag)
  • YPYDVPDYA Antibodies against the above tags are commercially available, e.g. from Alpha Diagnostic International, Inc., USA, and from Aves Lab, Inc., USA.
  • polypeptide of the present invention or the polypeptide part of a conjugate of the invention, optionally in glycosylated form may be produced by any suitable method known in the art. Such methods include constructing a nucleotide sequence encoding the polypeptide and expressing the sequence in a suitable transformed or transfected host. However, polypeptides of the invention may be produced, albeit less efficiently, by chemical synthesis or a combination of chemical synthesis or a combination of chemical synthesis and recombinant DNA technology.
  • the invention thus encompasses a method for preparing a single-chain multimeric polypeptide or polypeptide conjugate as disclosed herein, comprising culturing a recombinant host cell comprising a single nucleotide sequence encoding said polypeptide in a suitable culture medium under conditions permitting expression of the nucleotide sequence, and recovering the resulting polypeptide from the cell culture, followed, where appropriate, by reacting the polypeptide with a polymer molecule or other non-polypeptide moiety under conditions permitting conjugation to take place so as to result in a polypeptide conjugate, and recovering the conjugate.
  • the nucleotide sequence encoding a multimeric polypeptide of the invention, or the polypeptide part of a conjugate of the invention may be constructed by isolating or synthe- sizing a nucleotide sequence encoding the parent polypeptide, and then changing the nucleotide sequence so as to effect introduction (i.e. insertion or substitution) or deletion (i.e. removal or substitution) of the relevant amino acid residue(s).
  • the nucleotide sequence may be conveniently modified by site-directed mutagenesis in accordance with conventional methods.
  • the nucleotide sequence may be prepared by chemical synthesis, e.g.
  • oligonucleotide synthesizer by using an oligonucleotide synthesizer, wherein oligonucleotides are designed based on the amino acid sequence of the desired polypeptide, and preferably selecting those codons that are favored in the host cell in which the recombinant polypeptide will be produced.
  • oligonucleotides coding for portions of the desired polypeptide may be synthesized and assembled by PCR, ligation or ligation chain reaction (LCR) (Barany, PNAS 88:189-193, 1991).
  • LCR ligation or ligation chain reaction
  • the individual oligonucleotides typically contain 5' or 3' overhangs for complementary assembly.
  • Suitable mutations may be introduced by, e.g., site-directed mutagenesis as de- scribed by Sambrook et al. (Molecular Cloning: A Laboratory Manual, Second Edition, 1989), or by random mutagenesis or DNA shuffling, e.g. as described below followed by screening for sequences coding for polypeptides with the desired activity. Screening may be carried out by an assay method as described below.
  • Random mutagenesis (whether performed in the whole nucleotide sequence or one or more selected regions thereof) may be performed by any suitable method.
  • random mutagenesis is performed using a suitable physical or chemical mutagenizing agent, a suitable oligonucleotide, PCR generated mutagenesis or any combination of these mutagenizing agents/methods according to state of the art technology, e.g. as disclosed in WO 97/07202.
  • Error prone PCR generated mutagenesis e.g. as described by J.O. Deshler (1992),
  • GATA 9(4): 103-106 and Leung et al, Technique (1989) Vol. 1, No. 1, pp. 11-15, is particularly useful for mutagenesis of longer peptide stretches (corresponding to nucleotide sequences containing more than 100 bp) or entire genes, and is preferably performed under conditions that increase the misincorporation of nucleotides.
  • Random mutagenesis based on doped or spiked oligonucleotides is of particular use for mutagenesis of one or more regions containing shorter nucleotide sequences (normally containing less than 100 nucleotides per region). Mutagenesis of several regions is conveniently conducted by using several doped oligonucleotides and combining them by PCR.
  • Doped or spiked oligonucleotides may also be used for random mutagenesis of nucleotide sequences encoding longer peptide stretches or entire genes when it is desirable to be able to control the random mutagenesis to a higher extent than what is possible with error prone PCR generated mutagenesis.
  • random mutagenesis of one or more selected regions of a nucleotide sequence encoding the polypeptide of interest is performed using PCR generated mutagene- sis, in which one or more suitable oligonucleotide probes which flank the area to be mutagenized are used.
  • oligonucleotide probes which flank the area to be mutagenized are used.
  • doped or spiked oligonucleotides is used for mutagenesis of selected peptide stretches.
  • the doping or spiking can be designed to introduce any kind of amino acid residue and/or to avoid a codon for an unwanted amino acid residue (by lowering the amount of or completely avoiding the nucleotides resulting in this codon).
  • the doping may be designed on the basis of the skilled person's intelligent consideration of nucleotide doping (in accordance with generally known principles), by use of a suitable algorithm, e.g. a computer program which is based on the algorithm described by Siderovski DP and Mak TW, Comput. Biol. Med. (1993) Vol. 23, No. 6, pp. 463-474 or Jensen et al. Nucleic Acids Research, 1998, Vol. 26, No. 3 or by using trinucleotides (Sondek, J. and Shortle, D., Proc. Natl. Acad. Sci, USA, Vol. 89, pp.
  • a suitable algorithm e.g. a computer program which is based on the algorithm described by Siderovski DP and Mak TW, Comput. Biol. Med. (1993) Vol. 23, No. 6, pp. 463-474 or Jensen et al. Nucleic Acids Research, 1998, Vol. 26, No. 3 or by using trinucle
  • the doped or spiked oligonucleotide can be incorporated into the nucleotide sequence encoding the polypeptide of interest by any published technique using e.g. PCR, LCR or any DNA polymerase or ligase.
  • Random mutagenesis may be performed in two, three, four, five, six or more regions at the same time by synthesizing doped oligonucleotides covering each region and assembling the oligonucleotides by state of the art technologies, for example by a PCR method.
  • One convenient PCR method involves a PCR reaction wherein the nucleotide sequence encoding the polypeptide of interest is used as a template and the doped oligonucleotides are used as primers.
  • cloning primers localized outside the targeted regions may be used.
  • the resulting PCR product can either be directly cloned into an appropriate expression vector or gel purified and amplified in a second PCR reaction using the cloning primers and cloned into an appropriate expression vector.
  • the random mutagenesis may also cover random introduction of insertions or deletions.
  • the insertions are made so as to be in reading frame, e.g. by performing multiple introduction of three nucleotides as described by Hallet et al., Nucleic Acids Res. 1997, 25(9):1866-7 and Sondek and Shortle, PNAS USA 1992, 89(8):3581-5.
  • the nucleotide sequence(s) or nucleotide sequence region(s) to be mutagenized are typically present on a suitable vector such as a plasmid or a bacteriophage, which as such is incubated with or otherwise exposed to the mutagenizing agent.
  • the nucleotide sequence(s) to be mutagenized may also be present in a host cell either by being integrated into the ge- nome of said cell or by being present on a vector harboured in the cell.
  • the nucleotide sequence to be mutagenized is in isolated form.
  • the nucleotide sequence is preferably a DNA sequence such as a cDNA, genomic DNA or synthetic DNA sequence.
  • a modified conjugated single-chain polypeptide of the invention may be prepared by a) expressing a random mutagenized library of nucleotide sequences encoding a parent polypeptide in single-chain form, b) conjugating one or more non-polypeptide moieties to the polypeptide variants expressed in step a), c) screening the resulting conjugates for agonist activity or receptor-binding, d) selecting polypeptide conjugates having such capability, and e) optionally subjecting the nucleotide sequence encoding the polypeptide part of a polypeptide conjugate selected in step d) to one or more repeated cycles of steps a)-d).
  • the expression step a) can be conducted in any suitable manner, and conveniently as described further below.
  • the random mutagenized library is prepared by subjecting a nucleotide sequence encoding the parent polypeptide in single-chain form to random mutagenesis so as to create a large number of mutated nucleotide sequences.
  • the random mutagenesis may be entirely random, both with respect to where in the nucleotide sequence the mutagenesis occurs and with respect to the nature of mutagenesis.
  • the random mutagenesis may be conducted so as to randomly mutate one or more selected regions of the polypeptide, in particular a receptor-binding site thereof.
  • the library is typically present in a host cell, from which expression is achieved.
  • a host cell which is capable of a reasonable transformation frequency such as bacterium, e.g. E. coli, yeast, e.g. S. cereviciae, or fungus.
  • a high throughput transfection system of mammalian cells or other cells capable of a desirable post- translational modification (such as in vivo glycosylation) may be employed, for example using CHO (Chinese Hamster Ovary), COS or BHK (Baby Hamster Kidney) cells.
  • Conjugation step b) is conveniently conducted as described above in connection with conjugation to a polymer or an oligosaccharide moiety.
  • the screening step c) is an important element of the method according to this embodiment of the invention.
  • the screening is conveniently conducted as a primary screening for activating or receptor-binding capability, e.g. based on the principles disclosed in the section entitled "Assay”.
  • steps a-d) are performed in a high throughput screening system.
  • steps a)-d) are performed in a robotized system, wherein the expression from the random mutagenized library of nucleotide sequences is achieved in microtiter plates, the resulting supernatant is transferred to a different microtiter plate, preferably under conditions allowing immobilization of the polypeptides, and optionally under conditions where the receptor-binding site of the polypeptide is blocked, e.g. by a suitable receptor, receptor analogue or antibody, and/or the polypeptide is provided with a tag, e.g. of the type described above.
  • the optionally immobilized, blocked and/or tagged polypeptides are subjected to conjugation to a non-polypeptide moiety while present in the microtiter plate and the resulting polypeptide conjugates present in the microtiter plate are subjected to the relevant screening. Subsequently, selected positive polypeptide conjugates are subjected to further characterization, including secondary screening.
  • nucleotide sequence encoding the polypeptide is inserted into a recombinant vector and operably linked to control sequences necessary for expression of the polypeptide in the desired transformed host cell.
  • polypeptide conjugate can be prepared in a high throughput screening system allowing production and screening of a high number of different polypeptides in a short time. This is in particular suitable in the following situations: • obtaining an improved binding affinity
  • Nucleotide sequence modification methods suitable for producing polypeptide vari- ants for high throughput screening further include for instance methods which involve homologous cross-over such as disclosed in US 5,093,257, and methods which involve gene shuffling, i.e. recombination between two or more homologous nucleotide sequences resulting in new nucleotide sequences having a number of nucleotide alterations when compared to the starting nucleotide sequences.
  • Gene shuffling also known as DNA shuffling
  • the relevant parts of the nucleotide sequences are preferably at least 50% identical, such as at least 60% identical, more preferably at least 70% identical, such as at least 80% identical.
  • the recombination can be performed in vitro or in vivo.
  • WO 97/07205 An example of a suitable in vivo shuffling method is disclosed in WO 97/07205.
  • Other techniques for mutagenesis of nucleic acid sequences by in vitro or in vivo recombination are disclosed e.g. in WO 97/20078 and US 5,837,458.
  • specific shuffling techniques include "family shuffling", “synthetic shuffling” and "in silico shuffling”.
  • Family shuffling involves subjecting a family of homologous genes from different species to one or more cycles of shuffling and subsequent screening or selection.
  • Family shuffling techniques are disclosed e.g. by Crameri et al. (1998), Nature, vol. 391, pp. 288- 291; Christians et al. (1999), N ⁇ twre Biotechnology, vol. 17, pp. 259-264; Chang et al.
  • Synthetic shuffling involves providing libraries of overlapping synthetic oligonucleotides based e.g. on a sequence alignment of homologous genes of interest. The synthetically generated oligonucleotides are recombined, and the resulting re- combinant nucleic acid sequences are screened and if desired used for further shuffling cycles. Synthetic shuffling techniques are disclosed in WO 00/42561.
  • In silico shuffling refers to a D ⁇ A shuffling procedure which is performed or modelled using a computer system, thereby partly or entirely avoiding the need for physically manipulating nucleic acids. Techniques for in silico shuffling are disclosed in WO 00/42560. It should of course be understood that not all vectors and expression control sequences function equally well to express the nucleotide sequence encoding a polypeptide described herein. Neither will all hosts function equally well with the same expression system. However, one skilled in the art will be able to make a selection among these vectors, expression control sequences and hosts without undue experimentation. For example, in selecting a vector, the host must be considered because the vector must replicate in it or be able to integrate into the chromosome.
  • the vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, should also be considered.
  • an expression control sequence a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its controllability, and its compatibility with the nucleotide sequence encoding the polypeptide, particularly as regards potential secondary structures.
  • Hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded for by the nucleotide sequence, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture requirements, and ease of purification of the products encoded by the nucleotide sequence.
  • the recombinant vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
  • the vector is one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
  • the vector is preferably an expression vector in which the nucleotide sequence encoding the polypeptide of the invention is operably linked to additional segments required for transcription of the nucleotide sequence.
  • the vector is typically derived from plasmid or viral DNA.
  • suitable expression vectors for expression in the host cells mentioned herein are commercially available or described in the literature.
  • Useful expression vectors for eukaryotic hosts include, for example, vectors comprising expression control sequences from SV40, bovine papilloma virus, adenovirus and cytomegalo virus. Specific vectors are, e.g., pCDNA3.1(+) ⁇ Hyg (Invitrogen, Carlsbad, CA, USA) and pCI-neo
  • Useful expression vectors for yeast cells include the 2 ⁇ plasmid and derivatives thereof, the POT1 vector (US 4,931,373), the pJSO37 vector described in Okkels, Ann. New York Acad. Sci. 782, 202-207, 1996, and pPICZ A, B or C (Invitrogen).
  • Useful vectors for insect cells include pVL941, pBG311 (Cate et al., "Isolation of the Bovine and Human Genes for Mullerian Inhibiting Substance and Expression of the Human Gene in Animal Cells", Cell, 45, pp.
  • Useful expression vectors for bacterial hosts include known bacterial plasmids, such as plasmids from E. coli, including pBR322, pET3a and pET12a (both from Novagen Inc., WI, USA), wider host range plasmids, such as RP4, phage DNAs, e.g. the numerous derivatives of phage lambda, e.g. NM989, and other DNA phages, such as M13 and filamentous single stranded DNA phages.
  • known bacterial plasmids such as plasmids from E. coli, including pBR322, pET3a and pET12a (both from Novagen Inc., WI, USA)
  • wider host range plasmids such as RP4, phage DNAs, e.g. the numerous derivatives of phage lambda, e.g. NM989, and other DNA phages, such as M13 and filamentous single stranded
  • vectors for use in this invention include those that allow the nucleotide sequence encoding the polypeptide to be amplified in copy number.
  • amplifiable vectors are well known in the art. They include, for example, vectors able to be amplified by DHFR amplification (see, e.g., Kaufman, US 4,470,461, Kaufman and Sharp, "Construction Of A Modular Dihydrafolate Reductase cDNA Gene: Analysis Of Signals Utilized For Efficient Expression", Mol. Cell. Biol, 2, pp. 1304-19 (1982)) and glutamine synthetase ("GS”) am- plification (see e.g. US 5,122,464 and EP 338,841).
  • DHFR amplification see, e.g., Kaufman, US 4,470,461, Kaufman and Sharp, "Construction Of A Modular Dihydrafolate Reductase cDNA Gene: Analysis Of Signals Utilized For Efficient Expression", Mol
  • the recombinant vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
  • a DNA sequence enabling the vector to replicate in the host cell in question.
  • An example of such a sequence is the S V40 origin of replication.
  • suitable sequences enabling the vector to replicate are the yeast plasmid 2 ⁇ replication genes REP 1-3 and origin of replication.
  • the vector may also comprise a selectable marker, e.g. a gene whose product complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or the Schizosaccharomyces pombe TPI gene (described by P.R. Russell, Gene 40, 1985, pp. 125-130), or one which confers resistance to a drug, e.g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.
  • selectable markers include ura3 and leu2.
  • selectable markers include amdS, pyrG, arcB, niaD and sC.
  • control sequences is defined herein to include all components that are necessary or advantageous for the expression of the polypeptide of the invention.
  • Each con- trol sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide.
  • control sequences include, but are not limited to, a leader sequence, polyadenyla- tion sequence, propeptide sequence, promoter, enhancer or upstream activating sequence, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter.
  • a wide variety of expression control sequences may be used in the present invention.
  • Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors as well as any sequence known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.
  • suitable control sequences for directing transcription in mammalian cells include the early and late promoters of SV40 and adenovirus, e.g.
  • the adenovirus 2 major late promoter the MT-1 (metallothionein gene) promoter, the human cytomegalo virus immediate-early gene promoter (CMV), the human elongation factor l (EF-l ) promoter, the Drosophila minimal heat shock protein 70 promoter, the Rous Sarcoma Virus (RSV) promoter, the human ubiquitin C (UbC) promoter, the human growth hormone terminator, S V40 or adenovirus Elb region polyadenylation signals and the Kozak consensus sequence (Kozak, M. JMol Biol 1987 Aug 20;196(4):947-50).
  • a synthetic intron may be inserted in the 5' untranslated region of the nucleotide sequence encoding the polypeptide.
  • An example of a synthetic intron is the synthetic intron from the plasmid pCI-Neo (available from Promega Corporation, WI, USA).
  • control sequences for directing transcription in insect cells in- elude the polyhedrin promoter, the P10 promoter, the Autographa califomica polyhedrosis virus basic protein promoter, the baculovirus immediate early gene 1 promoter, the bacu- lovirus 39K delayed-early gene promoter, and the S V40 polyadenylation sequence.
  • suitable control sequences for use in yeast host cells include the promoters of the yeast ⁇ -mating system, the yeast triose phosphate isomerase (TPI) promoter, promoters from yeast glycolytic genes or alcohol dehydrogenase genes, the ADH2-4c promoter, and the inducible GAL promoter.
  • TPI yeast triose phosphate isomerase
  • suitable control sequences for use in filamentous fungal host cells include the ADH3 promoter and terminator, a promoter derived from the genes encoding Aspergillus oryzae TAKA amylase triose phosphate isomerase or alkaline protease, an A. niger -amylase, A. niger or A. nidulans glucoamylase, A. nidulans acetami- dase, Rhizomucor miehei aspartic proteinase or lipase, the TPIl terminator and the ADH3 terminator.
  • suitable control sequences for use in bacterial host cells include promoters of the lac system, the trp system, the TAC or TRC system, and the major promoter regions of phage lambda.
  • the presence or absence of a signal peptide will e.g. depend on the expression host cell used for the production of the polypeptide to be expressed (whether it is an intracellular or extracellular polypeptide) and whether it is desirable to obtain secretion.
  • the signal peptide may conveniently be derived from a gene encoding an Aspergillus sp. amylase or glucoamylase, a gene encoding a Rhizomucor miehei lipase or protease or a Humicola lanuginosa lipase.
  • the signal peptide is preferably derived from a gene encoding A. oryzae TAKA amylase, A.
  • the signal peptide may conveniently be derived from an insect gene (cf. WO 90/05783), such as the Lepidopteran manduca sexta adipokinetic hormone precursor, (cf.
  • honeybee melittin Invitro- gen
  • ecdysteroid UDPglucosyltransferase egt
  • hpl human pancreatic lipase
  • a preferred signal peptide for use in mammalian cells is e.g. the murine Ig kappa light chain signal peptide (Coloma, M (1992) J. lmm. Methods 152:89-104).
  • suitable signal peptides For use in yeast cells, suitable signal peptides have been found to be the ⁇ -f actor signal peptide from S. cereviciae (cf. US 4,870,008), a modified carboxypeptidase signal peptide (cf. L.A. Vails et al., Cell 48, 1987, pp. 887-897), the yeast BAR1 signal peptide (cf. WO 87/02670), the yeast aspartic protease 3 (YAP3) signal peptide (cf. M. Egel-Mitani et al., Yeast 6, 1990, pp. 127-137), and the synthetic leader sequence TA57 (WO98/32867).
  • a suitable signal peptide For use in E. coli cells a suitable signal peptide has been found to be the signal peptide ompA (EP 581 821).
  • the nucleotide sequence of the invention encoding a polypeptide may optionally also include a nucleotide sequence that encodes a signal peptide.
  • the signal peptide is present when the polypeptide is to be secreted from the cells in which it is expressed. Such a signal peptide, if present, should be one recognized by the cell chosen for expression of the polypeptide.
  • the signal peptide may be homologous (e.g. be that normally associated with the native peptide) or heterologous (i.e. originating from another source) to the polypeptide or may be homologous or heterologous to the host cell, i.e.
  • the signal peptide may be prokaryotic, e.g. derived from a bacterium such as E. coli, or eukaryotic, e.g. derived from a mammalian, insect or yeast cell.
  • Any suitable host may be used to produce the polypeptide or polypeptide part of the conjugate of the invention, including bacteria, fungi (including yeasts), plants, insects, mammals or other animals, or an appropriate animal cell line or another cell line.
  • bacterial host cells include gram-positive bacteria such as strains of Bacillus, e.g. B. bre- vis or B. subtilis, Pseudomonas or Streptomyces, or gram-negative bacteria such as strains of E. coli.
  • the introduction of a vector into a bacterial host cell may, for instance, be effected by protoplast transformation (see e.g. Chang and Cohen, 1979, Molecular General Genetics 168: 111-115), using competent cells (see e.g.
  • filamentous fungal host cells include strains of Aspergillus, e.g. A. oryzae, A. niger or A. nidulans, Fusarium or Trichoderma.
  • Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known per se. Suitable procedures for transforma- tion of Aspergillus host cells are described in EP 238 023 and US 5,679,543. Suitable methods for transforming Fusarium species are described by Malardier et al., 1989, Gene 78: 147-156 and WO 96/00787. Examples of suitable yeast host cells include strains of Sac- charomyces, e.g. S. cerevisiae, Schizosaccharomyces, Klyveromyces, Pichia, such as P. pas- toris or P. methanolica, Hansenula, such as H.
  • Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.I., editors, Guide to Yeast Genetics and Molecular Biology, Methods in Enzymol- ogy, Volume 194, pp. 182-187, Academic Press, Inc., New York; Ito et al., 1983, lournal of Bacteriology 153: 163; Hinnen et al., 1978, PNAS USA 75: 1920: and as disclosed by Clon- tech Laboratories, Inc., Palo Alto, CA, USA (in the product protocol for the YeastmakerTM Yeast Transformation System Kit).
  • suitable insect host cells include a Lepidoptora cell line, such as Spo- dopterafrugiperda (Sf9 or Sf21) or Trichoplusioa ni cells (High Five) (US 5,077,214). Transformation of insect cells and production of heterologous polypeptides therein may be performed as described by Invitrogen.
  • suitable mammalian host cells include Chinese hamster ovary (CHO) cell lines, (e.g. CHO-K1 ; ATCC CCL-61), Green Monkey cell lines (COS) (e.g. COS 1 (ATCC CRL-1650), COS 7 (ATCC CRL-1651)); mouse cells (e.g.
  • NS/O Baby Hamster Kidney
  • BHK Baby Hamster Kidney
  • human cells e.g. HEK 293 (ATCC CRL-1573)
  • Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland, USA.
  • Methods for introducing exogeneous DNA into mammalian host cells include calcium phosphate-mediated transfection, electroporation, DEAE-dextran mediated transfection, liposome-mediated transfection, viral vectors and the transfection method described by Life Technologies Ltd, Paisley, UK using Lipofectamin 2000. These methods are well known in the art and e.g.
  • the cells are cultivated in a nu- trient medium suitable for production of the polypeptide using methods known in the art.
  • the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated.
  • the cultivation takes place in a suitable nu- trient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g. in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.
  • the resulting polypeptide may be recovered by methods known in the art.
  • the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray drying, evaporation or precipitation.
  • the polypeptides may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g. ion exchange, affinity, hydrophobic, chro- matofocusing, and size exclusion), electrophoretic procedures (e.g. preparative isoelectric focusing), differential solubility (e.g. ammonium sulfate precipitation), SDS-PAGE, or extraction (see e.g. Protein Purification, J.-C.
  • the multimeric polypeptides and conjugates of the invention may be used for the manufacture of a medicament for treatment of diseases in mammals, in particular humans.
  • the exact dose of a particular polypeptide or conjugate to be administered will depend on e.g. the disease, the administration schedule, whether it is administered alone or in conjunc- tion with other therapeutic agents, the serum half-life of the compositions, and the general health of the patient.
  • the polypeptide or conjugate will advantageously be administered in an "effective amount", meaning an amount that prevents or alleviates, to any degree, or eliminates, the condition being treated.
  • Pharmaceutical formulations of the polypeptide or conjugate of the invention are typically administered in a composition that includes one or more pharmaceutically acceptable carriers or excipients. Such pharmaceutical compositions may be prepared in a manner known per se in the art to result in a polypeptide pharmaceutical that is sufficiently storage- stable and is suitable for administration to humans or animals.
  • the polypeptide or conjugate of the invention can be used "as is" and/or in a salt form thereof.
  • Suitable salts include, but are not limited to, salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium and magnesium, as well as e.g. zinc salts. These salts or complexes may by present as a crystalline and/or amorphous structure.
  • “Pharmaceutically acceptable” means a carrier or excipient that at the dosages and concentrations employed does not cause any untoward effects in the patients to whom it is administered.
  • Such pharmaceutically acceptable carriers and excipients are well known in the art (see Remington's Pharmaceutical Sciences, 18th edition, A. R. Gennaro, Ed., Mack Publishing Company [1990]; Pharmaceutical Formulation Development of Peptides and Proteins, S. Frokjaer and L. Hovgaard, Eds., Taylor & Francis [2000] ; and Handbook of Pharmaceutical Excipients, 3rd edition, A. Kibbe, Ed., Pharmaceutical Press [2000]).
  • the polypeptides and conjugates of the invention will be administered to patients in a therapeutically effective dose.
  • therapeutically effective dose herein is meant a dose that is sufficient to produced the desired effects in relation to the condition for which it is administered. The exact dose will depend on the disorder to be treated, and will be ascer- tainable by one skilled in the art using known techniques. Mix of drugs
  • the pharmaceutical composition of the invention may be administered alone or in conjunction with other therapeutic agents. These agents may be incorporated as part of the same pharmaceutical composition or may be administered separately from the polypeptide or conjugate of the invention, either concurrently or in accordance with another treatment schedule. In addition, the polypeptide, conjugate or pharmaceutical composition of the invention may be used as an adjuvant to other therapies.
  • a "patient” for the purposes of the present invention includes both humans and other mammals. Thus the methods are applicable to both human therapy and veterinary applications.
  • compositions and administration route The pharmaceutical composition of the polypeptide or conjugate of the invention may be formulated in a variety of forms, e.g. as a liquid, gel, lyophilized, or as a compressed solid. The preferred form will depend upon the particular indication being treated and will be readily able to be determined by one skilled in the art.
  • the administration of the formulations of the present invention can be performed in a variety of ways, including, but not limited to, subcutaneously, intravenously, orally, in- tracerebrally, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, intraocularly, or in any other acceptable manner.
  • the formulations can be administered continuously by infusion, although bolus injection is acceptable, using techniques well known in the art, such as pumps or implantation.
  • compositions designed for parenteral administration.
  • parenteral formulations may also be pro- vided in frozen or in lyophilized form.
  • the latter form is often used to enhance the stability of the active compound contained in the composition under a wider variety of storage conditions, as it is recognized by those skilled in the art that lyophilized preparations are generally more stable than their liquid counterparts.
  • Such lyophilized preparations are reconstituted prior to use by the addition of one or more suitable pharmaceutically acceptable diluents such as sterile water for injection or sterile physiological saline solution.
  • parenterals In case of parenterals, they are prepared for storage as lyophilized formulations or aqueous solutions by mixing, as appropriate, the polypeptide having the desired degree of purity with one or more pharmaceutically acceptable carriers, excipients or stabilizers typically employed in the art (all of which are termed "excipients"), for example buffering agents, stabilizing agents, preservatives, isotonifiers, non-ionic detergents, antioxidants and/or other miscellaneous additives.
  • excipients typically employed in the art
  • Buffering agents help to maintain the pH in the range which approximates physio- logical conditions. They are typically present at a concentration ranging from about 2 mM to about 50 mM
  • Suitable buffering agents for use with the present invention include both organic and inorganic acids and salts thereof such as citrate buffers (e.g., monosodium citrate- disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-monosodium citrate mixture, etc.), succinate buffers (e.g., succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.), fumarate buffers (e.g., fumaric acid- monosodium fumarate mixture, fumaric
  • Preservatives are added to retard microbial growth, and are typically added in amounts of e.g. about 0.1%-2% (w/v).
  • Suitable preservatives for use with the present invention include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octade- cyldimethylbenzyl ammonium chloride, benzalkonium halides (e.g. benzalkonium chloride, bromide or iodide), hexamethonium chloride, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol and 3-pentanol.
  • Isotonicifiers are added to ensure isotonicity of liquid compositions and include polyhydric sugar alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol.
  • Polyhydric alcohols can be present in an amount between 0.1% and 25% by weight, typically 1% to 5%, taking into account the rela- tive amounts of the other ingredients.
  • Stabilizers refer to a broad category of excipients which can range in function from a bulking agent to an additive which solubilizes the therapeutic agent or helps to prevent denaturation or adherence to the container wall.
  • Typical stabilizers can be polyhydric sugar alcohols (enumerated above); amino acids such as arginine, lysine, glycine, glutamine, as- paragine, histidine, alanine, omithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, etc., organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinisitol, galactitol, glycerol and the like, including cyclitols such as inositol; polyethylene glycol; amino acid polymers; sulfur-containing reducing agents, such as
  • proteins such as human serum albumin, bovine serum albumin, gelatin or immunoglobulins
  • hydrophilic polymers such as polyvinylpyrrolidone
  • monosaccharides such as xylose, mannose, fructose and glucose
  • disaccharides such as lactose, maltose and sucrose
  • trisaccharides such as raffi- nose, and polysaccharides such as dextran.
  • Stabilizers are typically present in the range of from 0.1 to 10,000 parts by weight based on the active protein weight.
  • Non-ionic surfactants or detergents may be present to help solubilize the therapeutic agent as well as to protect the therapeutic polypeptide against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stress without causing denaturation of the polypeptide.
  • Suitable non-ionic sur- factants include polysorbates (20, 80, etc.), polyoxamers (184, 188 etc.), Pluronic® polyols, polyoxyethylene sorbitan monoethers (Tween®-20, Tween®-80, etc.).
  • Additional miscellaneous excipients include bulking agents or fillers (e.g. starch), chelating agents (e.g. EDTA), antioxidants (e.g., ascorbic acid, methionine, vitamin E) and cosol vents.
  • the active ingredient may also be entrapped in microcapsules prepared, for example, by coascervation techniques or by interfacial polymerization, for example hydroxy- methylcellulose, gelatin or poly-(methylmethacylate) microcapsules, in colloidal drug delivery systems (for example liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • Parenteral formulations to be used for in vivo administration must be sterile. This is readily accomplished, for example, by filtration through sterile filtration membranes.
  • sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the polypeptide or conjugate, the matrices having a suitable form such as a film or microcapsules.
  • sustained-release ma- trices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate) or poly(vinylalcohol)), polylactides, copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene- vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the ProLease® technology or Lupron Depot® (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.
  • polymers such as ethylene- vinyl acetate and lactic acid-glycolic acid enable release of molecules for long periods such as up to or over 100 days
  • certain hydrogels release proteins for shorter time periods.
  • encapsulated polypeptides remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved.
  • stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
  • Formulations suitable for use with a nebulizer will typically comprise the polypeptide or conjugate dissolved in water at a concentration of, e.g., about 0.01 to 25 mg of conjugate per mL of solution, preferably about 0.1 to 10 mg/mL.
  • the for- mulation may also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure), and/or human serum albumin ranging in concentration from 0.1 to 10 mg/ml.
  • buffers that may be used are sodium acetate, citrate and glycine.
  • the buffer will have a composition and molarity suitable to adjust the solu- tion to a pH in the range of 3 to 9.
  • buffer molarities of from 1 mM to 50 mM are suitable for this purpose.
  • sugars which can be utilized are lactose, maltose, mannitol, sorbitol, trehalose, and xylose, usually in amounts ranging from 1% to 10% by weight of the formulation.
  • the nebulizer formulation may also contain a surfactant to reduce or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.
  • Various conventional surfactants can be employed, such as polyoxyethylene fatty acid esters and alcohols, and polyoxyethylene sorbitan fatty acid esters. Amounts will generally range between 0.001% and 4% by weight of the formulation.
  • An especially preferred surfactant for purposes of this invention is polyoxyethylene sorbitan monooleate.
  • Formulations for use with a metered dose inhaler device will generally comprise a finely divided powder. This powder may be produced by lyophilizing and then milling a liquid conjugate formulation and may also contain a stabilizer such as human serum albumin (HSA). Typically, more than 0.5% (w/w) HSA is added. Additionally, one or more sugars or sugar alcohols may be added to the preparation if necessary.
  • HSA human serum albumin
  • Examples include lactose mal- tose, mannitol, sorbitol, sorbitose, trehalose, xylitol, and xylose.
  • the amount added to the formulation can range from about 0.01 to 200% (w/w), preferably from approximately 1 to 50%, of the conjugate present. Such formulations are then lyophilized and milled to the desired particle size.
  • the properly sized particles are then suspended in a propellant with the aid of a sur- factant.
  • the propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof.
  • Suitable surfactants include sorbitan tri- oleate and soya lecithin. Oleic acid may also be useful as a surfactant. This mixture is then loaded into the delivery device.
  • Formulations for powder inhalers will comprise a finely divided dry powder containing conjugate and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which facilitate dispersal of the powder from the device, e.g., 50% to 90% by weight of the formulation.
  • the particles of the powder shall have aerodynamic properties in the lung corresponding to particles with a density of about 1 g/cm 2 having a median diameter less than 10 micrometers, preferably between 0.5 and 5 micrometers, most preferably of between 1.5 and 3.5 micrometers.
  • the powders for these devices may be generated and/or delivered by methods disclosed in US 5,997,848, US 5,993,783, US 5,985,248, US 5,976,574, US 5,922,354, US 5,785,049 and US 5,654,007.
  • Mechanical devices designed for pulmonary delivery of therapeutic products include but are not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those of skill in the art.
  • nebulizers include but are not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those of skill in the art.
  • Specific examples of commercially available devices suitable for the practice of this invention are the UltraventTM nebulizer, manufactured by Mallinckrodt, Inc., St.
  • ASA Accessible Surface Area
  • the fractional ASA of the side chain atoms is computed by division of the sum of the ASA of the atoms in the side chain by a value representing the ASA of the side chain atoms of that residue type in an extended ALA-x-ALA tripeptide. See Hubbard, Campbell & Thornton (1991) J.Mol.Biol. 220, 507-530.
  • the CA atom is regarded as a part of the side chain of glycine residues but not for the remaining residues.
  • the following values are used as standard 100% ASA for the side chain:
  • Residues not detected in the structure are defined as having 100% exposure as they are thought to reside in flexible regions.
  • the distance between atoms is most easily determined using molecular graphics software, e.g. InsightU v. 98.0, MSI Inc.
  • amino acid residues to be modified in accordance with the present invention are preferably those whose side chains are surface exposed, in particular those with more than about 25% of the side chain exposed at the surface of the molecule, and more preferably those with more than 50% side chain exposure.
  • residues located in receptor interfaces are preferably excluded so as to avoid or at least minimize possible interference with receptor binding or activation.
  • residues that are less than lOA from the nearest Lys (Glu, Asp) CB-CB (CA for Gly) should also be excluded.
  • preferred positions for modification are in particular those that have a hydrophilic and/or charged residue, i.e. Asp, Asn, Glu, Gin, Arg, His, Tyr, Ser and Thr, positions that have an arginine residue being especially preferred. Identifying G-CSF amino acid residues for modification
  • the molecular graphics program Insight ⁇ v.98.0 was used to determine residues having their CB atom (CA in the case of glycine) at a distance of more than 15A from the nearest amine group, defined as the NZ atoms of lysine and the N atom of the N-terminal residue TI.
  • the following list includes the residues that fulfill this criteria in at least one of the 10 NMR structures.
  • G4 P5, A6, S7, S8, L9, PIO, Qll, L14, L15, L18, V21, R22, Q25, G26, D27, G28, A29, Q32, L35, C36, T38, Y39, C42, H43, P44, E45, E46, L47, V48, L49, L50, G51, H52, S53, L54, G55, 156, P57, W58, A59, P60, L61, S62, S63, C64, P65, S66, Q67, A68, L69, Q70, L71, A72, G73, C74, L75, S76, Q77, L78, H79, S80, G81, L82, F83, L84, Y85, Q86, G87, L88, L89, Q90, A91, L92, E93, G94, 195, S96, P97, E98, L99, G100, P101, T102, L103, D
  • CB atom (CA atom in the case of glycine) at a distance of more than lOA from the nearest acidic group, defined as the CG atoms of aspartic acid, the CD atoms of glutamic acid and the C atom of the C-terminal residue P174.
  • the following list includes the residues that fulfill this criteria in at least one of the 10 NMR structures.
  • Single chain G-CSF dimer and variants thereof are PEGylated at a concentration of 250 ⁇ g/ml in 50 mM sodium phosphate, 100 mM NaCl, pH 8.5.
  • the molar surplus of PEG is 100 times with respect to PEGylation sites on the protein.
  • the reaction mixture is placed in a thermo mixer for 30 minutes at 37°C at 1200 rpm. After 30 minutes, quenching of the reaction is obtained by adding a molar excess of glycine.
  • Cation exchange chromatography is applied to remove excess PEG, glycine and other by-products from the reaction mixture.
  • the PEGylation reaction mixture is diluted with 20 mM sodium citrate pH 2.5 until the ionic strength is less than 7 mS/cm. pH is adjusted to 2.5 using 5 N HC1.
  • the mixture is applied to an SP-sepharose FF column equilibrated with 20 mM sodium citrate pH 2.5. Unbound material is washed off the column using 4 column volumes of equilibration buffer.
  • PEGylated protein is eluted in three column vol- umes by adding 20 mM sodium citrate, 750 mM sodium chloride. Pure PEGylated G-CSF is concentrated and buffer exchange is performed using VivaSpin concentration devices, molecular weight cut-off (mwco): 10 kDa.
  • a polypeptide exhibiting single chain G-CSF dimer activity is expressed with a suitable tag, e.g. any of the tags exemplified in the general description above, and culture broth is transferred to one or more wells of a microtiter plate capable of immobilising the tagged polypeptide.
  • Ni-NTA nickel-nitrilotriacetic acid
  • the wells are washed in a buffer suitable for binding and subsequent PEGylation followed by incubating the wells with the activated PEG of choice.
  • a buffer suitable for binding and subsequent PEGylation As an example, M-SPA-PEG 5000 from Shearwater Corp. is used.
  • the molar ratio of activated PEG to polypeptide should be optimized, but will typically be greater than 10:1, e.g. up to about 100:1 or higher.
  • a suitable reaction time at ambient temperature typically around 1 hour, the reaction is stopped by removal of the activated PEG solution.
  • the conjugated protein is eluted from the plate by incubation with a suitable buffer.
  • Suitable elution buffers may contain imidazole, excess NTA or another chelating compound.
  • the conjugated protein is assayed for biological activity and immunogenicity as appropriate.
  • the tag may optionally be cleaved off using a method known in the art, e.g. using diaminopeptidase the Gin in pos -1 can be converted to pyroglutamyl with GCT (glutamylcyclotransf erase) and finally cleaved off with PGAP (pyro-glutamyl- aminopeptidase), giving the untagged protein.
  • GCT glutyroglutamylcyclotransf erase
  • PGAP pyro-glutamyl- aminopeptidase
  • the molecular weight of conjugated or non-conjugated single chain G-CSF dimer or variants thereof is determined by either SDS-PAGE, gel filtration, matrix assisted laser desorption mass spectrometry or equilibrium centrifugation.
  • SDS- PAGE provides information on the "apparent molecular weight".
  • the actual molecular weight can advantageously be determined using mass spectrometry.
  • SDS-PAGE is carried out using the NuPAGE® kit (Novex high-performance pre-cast gels) from InvitrogenTM. 15 ⁇ l of the samples are loaded onto NuPAGE® 4-12% Bis-Tris gels (Cat. No. NPO321) and eluted in NuPAGE® MES SDS running buffer (Cat. No. NPO002-02) for 35 minutes at 200 V and 120 mA.
  • the concentration of a polypeptide can be measured using optical density measurements at 280 nm, an enzyme-linked immunoadsorption assay (ELIS A), a radio- immunoassay (RIA), or other such immunodetection techniques well known in the art.
  • the polypeptide concentration in a sample can be measured with the Biacore® instrument using a Biacore® chip coated with an antibody specific for the polypeptide.
  • an antibody can be covalently coupled to the Biacore® chip by various chemistries.
  • the antibody can be non-covalently bound e.g. by means of an antibody specific for the Fc portion of the anti-polypeptide antibody.
  • the Fc specific antibody is first coupled covalently to the chip.
  • biotinylated antibodies can be immobilised using a streptavidin coated surface (e.g. Biacore Sensor Chip S A®) (Real-Time Analysis of Biomolecular Interactions, Nagata and Handa (Eds.), 2000, Springer Verlag, Tokyo; Biacore 2000 Instrument Handbook, 1999, Biacore AB).
  • a streptavidin coated surface e.g. Biacore Sensor Chip S A®
  • the polypeptide When the sample is flowed over the chip the polypeptide will bind to the coated an- tibody and the increase in mass can be measured.
  • a standard curve can be established and subsequently the concentration of the polypeptide in the sample can be determined.
  • the sensor chip After each injection of sample the sensor chip is regenerated by a suitable eluent (e.g. a low pH buffer) that removes the bound analyte.
  • the applied antibodies will be monoclonal antibodies raised against the wild-type polypeptide. Introduction of mutations or other manipulations of the wild-type polypeptide (extra glycosylations or polymer conjugations) may alter the recognition by such antibodies. Furthermore, such manipulations that give rise to an increased molecular weight of the polypeptide will result in an increased plasmon resonance signal. Conse- quently, it is necessary to establish a standard curve for every molecule to be tested.
  • NFS-60 Proliferation of the murine cell line NFS-60 (obtained from Dr. J. Uile, St. Jude Children's Research Hospital, Tennessee, USA) is dependent on the presence of active single chain G-CSF dimer in the growth medium.
  • the in vitro biological activity of single chain G-CSF dimer and variants thereof can be determined by measuring the number of dividing NFS-60 cells after addition of a single chain G-CSF dimer sample to the growth medium followed by incubation over a fixed period of time. NFS-60 cells are maintained in Iscoves DME Medium containing 10% w/w FBS
  • fetal bovine serum fetal bovine serum
  • Pen/Strep 10 ⁇ g per litre hG-CSF
  • 2 mM Glutamax Prior to sample addition, cells are washed twice in growth medium without hG-CSF and diluted to a concentration of 2.2 x 10 5 cells per ml. 100 ⁇ l of the cell suspension is added to each well of a 96 well microtiter plate (Corning).
  • Samples containing conjugated or non-conjugated single chain G-CSF dimer or variants thereof are diluted to concentrations between l.lxlO "6 M and l.lxlO "13 M in the growth medium.
  • 10 ⁇ l of each sample is added to 3 wells containing NFS-60 cells.
  • a control consisting of 10 ⁇ l of mammalian growth medium is added to 8 wells on each microtiter plate.
  • the cells are incubated for 48 hours (37°C, 5% CO 2 ) and the number of dividing cells in each well is quantified using the WST-1 cell proliferation agent (Roche Diagnostics GmbH, Mannheim, Germany). 0.01 ml WST-1 is added to the wells followed by incubation for 150 min. at 37°C in a 5% CO 2 air atmosphere.
  • WST-1 by mitochondrial dehydrogenases in viable cells results in the formation of formazan that is quantified by measuring the absorbance at 450 nm. The number of viable cells in each well is hereby quantified.
  • dose-response curves for each conjugated and non- conjugated single chain G-CSF dimer molecule or variants thereof are calculated, after which the EC50 value for each molecule can be determined.
  • This value is equal to the amount of active single chain G-CSF dimer protein that is necessary to obtain 50% of the maximum proliferation activity of non-conjugated human G-CSF.
  • the EC50 value is a direct measurement of the in vitro activity of the given protein, a lower EC50 value indicat- ing a higher specific activity.
  • the murine hematopoietic cell line BaF3 is transfected with a plasmid carrying the human G-CSF receptor and the promoter of the transcription regulator, fos, in front of the luciferase reporter gene.
  • a number of intracellular reactions lead to stimulation of fos expression, and consequently to expression of luciferase.
  • This stimulation is monitored by the Steady-GloTM Luciferase Assay System (Promega, Cat. No. E2510) whereby the in vitro activity of the G- CSF sample may be quantified.
  • BaF3/hGCSF-PJpfos-lux cells are maintained at 37°C in a humidified 5% CO 2 atmosphere in complete culture media (RPM-1640/HEPES (Gibco/BRL, Cat. No. 22400), 10% FBS (HyClone, characterized), lx Penicillin/Streptomycin (Gibco/BRL, Cat. No. 15140-122), lx L-Glutamine (Gibco/BRL, Cat. No. 25030-081), 10% WEHI-3 conditioned media (source of muIL-3), and grown to a density of 5 x 10 5 cells/mL (confluent). The cells are reseeded at about 2 x 10 4 cells/mL every 2-3 days.
  • log-phase cells are resuspended at 2 x 10 cells/mL in starving media (DMEM/F-12 (Gibco/BRL, Cat. No. 11039), 1% BSA (Sigma, Cat. No. A3675), lx Penicillin/Streptomycin (Gibco/BRL, Cat. No. 15140-122), lx L-Glutamine (Gibco/BRL, Cat. No. 25030-081), 0.1% WEFfl-3 conditioned media) and starved for 20 hours. The cells are washed twice with Dulbecco's PBS (BioWhittaker Cat. No. 17512F), and tested for viability using Trypan Blue viability staining.
  • Dulbecco's PBS BioWhittaker Cat. No. 17512F
  • the cells are resuspended in assay media (RPMI-1640 (phenol-red free, Gibco/BRL, Cat. No. 11835), 25 mM HEPES, 1% BSA (Sigma, Cat. No. A3675), lx Penicillin/Streptomycin (Gibco/BRL, Cat. No.
  • lx L-Glutamine (Gibco/BRL, Cat. No. 25030-081) at 4 x 10 6 cells/mL, and 50 ⁇ L are aliquotted into each well of a 96-well microtiter plate (Corning). Samples containing conjugated or non-conjugated single chain G-CSF dimer or variants thereof are diluted to concentrations between 1.1x10 M in the assay medium. 50 ⁇ l of each sample is added to 3 wells containing BaF3/hGCSF-R/pfos-lux cells. A negative control consisting of 50 ⁇ l of medium is added to 8 wells on each microtiter plate. The plates are mixed gently and incubated for 2 hours at 37°C.
  • the luciferase activity is measured by following the Promega Steady-GloTM protocol (Promega Steady-GloTM Luciferase Assay System, Cat. No. E2510). 100 ⁇ L of substrate is added per well followed by gentle mixing. Lu- minescence is measured on a TopCount luminometer (Packard) in SPC (single photon counting) mode.
  • Promega Steady-GloTM protocol Promega Steady-GloTM Luciferase Assay System, Cat. No. E2510
  • 100 ⁇ L of substrate is added per well followed by gentle mixing.
  • Lu- minescence is measured on a TopCount luminometer (Packard) in SPC (single photon counting) mode.
  • dose-response curves for each conjugated and non- conjugated single chain G-CSF dimer molecule or variants thereof are calculated, after which the EC50 value for each molecule can be determined.
  • binding of single-chain G-CSF dimer or variants thereof to the hG-CSF receptor is studied using standard binding assays.
  • the receptors may be purified extracellular receptor domains, receptors bound to purified cellular plasma membranes, or whole cells - the cellular sources being either cell lines that inherently express G-CSF receptors (e.g. NFS-60) or cells transfected with cDNAs encoding the receptors.
  • the ability of single-chain G-CSF dimer or variants thereof to compete for the binding sites with native G-CSF is analyzed by incubating with a labeled G-CSF-analog, for instance biotinylated hG-CSF or radioiodinated hG-CSF.
  • a labeled G-CSF-analog for instance biotinylated hG-CSF or radioiodinated hG-CSF.
  • An example of such an assay is described by Yamasaki et al. (Drugs.
  • the extracellular domains of the hG-CSF receptor can optionally be coupled to Fc and immobilized in 96 well plates.
  • Single-chain G-CSF dimer or variants thereof are subsequently added and the binding of these is detected using either specific anti-hG-CSF antibodies or biotinylated or radioiodinated hG-CSF.
  • An important aspect of the invention is the prolonged biological half -life that is obtained by construction of a single-chain G-CSF dimer conjugated to a polymer moiety.
  • the rapid decrease of hG-CSF serum concentrations has made it important to evaluate biological responses to treatment with conjugated and non-conjugated single-chain G-CSF dimers and variants thereof.
  • Measurement of in vivo biological half -life can be carried out as described below.
  • the rats On the day of arrival the rats were randomly allocated into groups of 6. The animals were acclimatised for a period of 7 days wherein individuals in poor condition or at extreme weights were rejected. The weight range of the rats at the start of the acclimatization period was 250-270g.
  • SPF Sprague Dawley rats were purchased from M & B A/S, Denmark. On the day of arrival the rats were randomly allocated into groups of 6. The animals were acclimatised for a period of 7 days wherein individuals in poor condition or at extreme weights were rejected. The weight range of the rats at the start of the acclimatization period was 250-270 g. 24 hours before administration of the single-chain G-CSF dimer samples the rats were injected i.p. with 50-100 mg per kg body weight of cyclophosphamide (CPA). At day 0, 100 ⁇ g per kg body weight of single-chain G-CSF dimer or a variant thereof was injected s.c.
  • CPA cyclophosphamide
  • Each single-chain G-CSF dimer sample was injected into a group of 6 randomized rats.
  • 5 ⁇ g per kg body weight of Neupogen® was injected s.c. into a group of 6 randomized rats at time 0, 24, 48, 72 and 96 hours.
  • Blood samples of 300 ⁇ l EDTA stabilized blood were drawn from a tail vein of the rats prior to dosing and at 6, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours after dosing. The blood samples were analyzed for total white blood cell counts. On the basis of these measurements the biological efficacy of conjugated and non-conjugated single-chain G-CSF dimer and variants thereof was evaluated.
  • the strength of the binding between a receptor and ligand can be measured using an enzyme-linked immunoadsorption assay (ELISA), a radio-immunoassay (RIA), or other such immunodetection techniques well known in the art.
  • ELISA enzyme-linked immunoadsorption assay
  • RIA radio-immunoassay
  • the ligand-receptor binding interaction may also be measured with the Biacore® instrument (Zhou et al., Biochemistry, 1993, 32, 8193-98; Faegerstram and O'Shannessy, 1993, In Handbook of Affinity Chromatogra- phy, 229-52, Marcel Dekker, Inc., NY).
  • the Biacore® technology allows one to bind receptor to a gold surface and to flow ligand over it. Plasmon resonance detection gives direct quantification of the amount of mass bound to the surface in real time. This technique yields both on and off-rate constants and thus a ligand-receptor dissociation constant and an
  • the reduced immunogenicity of a conjugate of the invention can be determined by use of an ELISA method measuring the immunoreactivity of the conjugate relative to a reference molecule or preparation.
  • the reference molecule or preparation is normally a recom- binant human G-CSF preparation such as Neupogen® or another recombinant human G- CSF preparation, e.g. an N-terminally PEGylated rhG-CSF molecule as described in US 5,824,784.
  • the ELISA method is based on antibodies from patients treated with one of these recombinant G-CSF preparations.
  • the immunogenicity is considered to be reduced when the conjugate of the invention has a statistically significant lower response in the assay than the reference molecule or preparation. Neutralisation of activity in the single-chain G-CSF dimer activity assay
  • Sera from patients treated with the G-CSF reference molecule or from immunised animals are used. Sera are added either in a fixed concentration (dilution 1:20-1 :500 (pt sera) or 20-1000 ng/ml (animal sera)) or in five-fold serial dilutions of sera starting at 1:20 (pt sera) or 1000 ng/ml (animal sera).
  • Single-chain G-CSF dimer conjugate is added either in seven fold-dilutions starting at 10 nM or in a fixed concentration (1-100 pM) in a total volume of 80/xl DMEM (Dulbecco's modified Eagle's medium) + 10% FCS (fetal calf serum). The sera are incubated for 1 hr. at 37°C with single-chain G-CSF dimer conjugate.
  • the samples (0.01 ml) are then transferred to 96 well tissue culture plates containing NFS-60 cells in 0.1 ml DMEM media. The cultures are incubated for 48 hours at 37°C in a 5% CO 2 air atmosphere. 0.01 ml WST-1 (WST-1 cell proliferation agent, Roche Diagnostics GmbH, Mannheim, Germany) is added to the cultures and incubated for 150 rnin. at 37°C in a 5% CO 2 air atmosphere. The cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases in viable cells results in the formation of formazan that is quantified by measuring the absorbance at 450 nm.
  • WST-1 WST-1 cell proliferation agent
  • Another DNA fragment consisting of a Bam HI digestion site, the Kozak consensus sequence (Kozak, M., JMol Biol, Aug. 1987; 196(4):947-50), a sequence encoding the hG-CSF signal peptide (SEQ ID NO:7), G-CSF copy 1 with the codon usage optimised for expression in CHO cells (SEQ ID NO:8) and G-CSF copy 2 (SEQ ID NO:5) in the single- chain G-CSF dimer and an Xba I digestion site, was also synthesised following the general procedure described by Stemmer et al. (1995), Gene 164, pp. 49-53. The DNA fragment was inserted into the Bam HI and Xba I digestion sites in plasmid pcDNA3.1(+) (Invitrogen) using standard DNA techniques. This resulted in plasmid pscG-CSFCHO.
  • the cells were pelleted by centrifuga- tion (4000 rpm, 2 minutes), the supernatant was discharged and the cells were resuspended in non-selective YPD medium (1% w/w yeast extract (Difco), 2% w/w peptone bacto (Difco), 3% w/w dextrose (Roquette)).
  • non-selective YPD medium 1% w/w yeast extract (Difco), 2% w/w peptone bacto (Difco), 3% w/w dextrose (Roquette)
  • SC-without-uracil medium 7.5 g per litre yeast nitrogen base w/o amino acids (Difco), 11.3 g per litre Bernstein acid (Merck), 6.8 g per litre NaOH (Merck), 5.6 g per litre casamino acid w/o vitamin, 0.1 g per litre tryptophan, 20 g per litre glucose (Sigma), 0.1 g per litre threonine).
  • SC-without-uracil medium 7.5 g per litre yeast nitrogen base w/o amino acids (Difco), 11.3 g per litre Bernstein acid (Merck), 6.8 g per litre NaOH (Merck), 5.6 g per litre casamino acid w/o vitamin, 0.1 g per litre tryptophan, 20 g per litre glucose (Sigma), 0.1 g per litre threonine).
  • the CHO Kl cell line (ATCC #CC1-61) was seeded in a T-25 flask in 5 ml DMEM/F-12 medium (Gibco # 31330-038) supplemented with 10% FBS and penicillin/streptomycin. The following day (at nearly 100% confluency) the transfection was prepared: 90 ⁇ l DMEM medium without supplements was aliquoted into a 14 ml polypropylene tube (Corning). 10 ⁇ l Fugene 6 (Roche) was added directly into the medium and incubated for 5 min at room temperature. In the meantime 5 ⁇ g plasmid pscG- CSFCHO was aliquoted into another 14 ml polypropylene tube. After incubation the Fugene 6 mix was added directly to the DNA solution and incubated for 15 min at room temperature. After incubation the whole volume was added drop-wise to the cell medium.
  • the primary transfection pool was subsequently sub-cloned by limited dilution (300 cells seeded in five 96-well plates) whereby stable cell lines expressing single chain G-CSF dimer was obtained.
  • the roller bottle was ready for production and the medium was shifted to the production medium: DMEM/F-12 medium without phenol red (Life Technologies # 21041) supple- mented with 1/100 ITS A (Life Technologies # 51300-044) [IT SA: Insulin (1.0 g/L) - Trans- ferrin (0.55 g/L) - Selenium (0.67 mg/L) supplement for Adherent cultures], 1/1000 EC- CYTE and P/S. During the production period the medium was exchanged every day.
  • the diluted sample was applied to an SP Sepharose FF column (20 ml) equilibrated in 50 mM Na acetate, pH 4.5 operated at a flow rate of 5 ml/min. Following application, the column was washed with equilibration buffer until the A 280 in the column effluent reached a stable level. Elution was performed at a flow rate of 3 ml/min using a linear gradient of NaCl (0 M to 0.75 M) in 50 mM Na acetate, pH 4.5 over 20 column volumes. Fractions of 2.4 ml were collected. The fractions containing single-chain G-CSF dimer were pooled.
  • Sample preparation before performing hydrophobic interaction chromatography was made by adding 4 volumes of 1 M ammonium sulphate, pH 8 to reach a final concentration of 800 mM ammonium sulphate. The pH of the sample was measured before loading and was found to be 8.
  • the sample was loaded onto a column packed with 5 ml ToyoPearl Phenylsepha- rose-650 equilibrated with 10 column volumes of 1 M ammonium sulphate, pH 8 at a flow rate of 2 ml/min.
  • the column was washed with 0.8 M ammonium sulphate until the A 280 in the column effluent reached a stable level.
  • Elution of the column was performed using a linear gradient (0.8 M ammonium sulphate, pH 8, to MilliQ filtered water) for 60 column volumes at a flow rate of 3 ml/min. Fractions of 2.5 ml were collected.
  • the concentration of single-chain G-CSF dimer in the fractions from the FflC column was determined by ELISA (Quantikine G-CSF ELISA assay, R&D Systems catalogue number DCS50).
  • Culture medium from the roller bottle cultivations of CHO cells expressing single chain G-CSF dimer was harvested and sterile filtered using a 0.22 ⁇ m filter.
  • the conductivity was adjusted to 75 mS/cm using 4 M sodium chloride and the conditioned medium was applied on a column of Phenyl Toyo Pearl 650 S resin equilibrated with 20 mM sodium phosphate, pH 7.0; 750 mM sodium chloride.
  • the column was washed to stable base line using the equilibration buffer and eluted stepwise using 20 mM sodium phosphate, pH 7.0.
  • Fractions containing sc-GCSF were pooled and adjusted with 50 mM sodium acetate to reach pH 4.5 and a conductivity below 7mS/cm.
  • the adjusted fractions were applied on a SP-sepharose FF (Pharmacia) at a flow rate of 150-300 cm/hour.
  • the column was washed and eluted by a step gradient 0-100% B-buffer (750 mM sodium chloride, 50 mM sodium acetate (pH 4.5) with increments of 10% B-buffer at a flow rate of 150 cm/hour.
  • B-buffer 750 mM sodium chloride, 50 mM sodium acetate (pH 4.5) with increments of 10% B-buffer at a flow rate of 150 cm/hour.
  • the frac- tions containing single chain G-CSF dimer were subsequently pooled.
  • amino acid sequence of the single-chain G-CSF dimer is given in SEQ ID NO:6.
  • the purity of purified single-chain G-CSF dimer was determined by reverse phase HPLC.
  • a single-chain G-CSF dimer sample was applied to a Vydac C ⁇ 8 reverse phase column (0.21 x 5 cm) and isocratically eluted with buffer A (0.1% TFA in water) and buffer B (0.1% TFA in acetonitril) using the following gradient: 0 - 5 minutes: 100% buffer A, 5 - 15 minutes: 0-40% buffer B, 15-35 minutes: 40-100% buffer B, 35-40 minutes; 100-0% buffer B.
  • the purity was determined to be higher than 90%.
  • the RP-HPLC result was confirmed by SDS-PAGE analysis.
  • the purified single-chain G-CSF dimer was analyzed by SDS-PAGE. A single band having an apparent molecular weight of 38 kDa was detected. MALDI-TOF mass spectrometry of purified single-chain G-CSF dimer showed that the size of the protein was 38.8 kDa corresponding to 2 times the molecular weight of hG-CSF.
  • the new single chain G-CSF dimer variants were made using plasmid pscG-CSFCHO as DNA template in the PCR reactions.
  • the following variants were constructed: Single chain G-CSF dimer (K16R) CO py ⁇ ,2 (i-e. with the substitution K16R in copy 1 and copy 2), single chain G-CSF dimer (K16R K34R) copy ⁇ ;2 , and single chain G-CSF dimer (K16R K34R K40R) copy ⁇ , 2 .
  • the variants were expressed in CHO cells and purified as described in Example 5.
  • SPA-PEG 5000, SPA-PEG 12000 and SPA-PEG 20000 were covalently linked to single chain G-CSF dimer and variants thereof purified from CHO cells as described above ("PEGylation of single chain G-CSF dimer and variants thereof in solu- tion").
  • PEGylation of single chain G-CSF dimer and variants thereof in solu- tion The apparent sizes of the PEGylated compounds as determined by SDS-PAGE are listed below.
  • CSF dimer and variants thereof were measured as described above in "Primary assay 2 - in vitro single chain G-CSF dimer activity assay".
  • the in vitro bioactivities determined on the basis of the measured EC50 values for each variant with and without conjugation of SPA- PEG to the available PEGylation sites, are listed below.
  • the values have been normalized with respect to the EC50 value of non-conjugated hG-CSF (Neupogen®), which in this assay is 30 pM. This value was measured simultaneously with that of the variants under identical assay conditions.
  • the values in the table thus indicate % specific activity relative to the activity of non-conjugated hG-CSF.
  • the level of white blood cells returned to normal only after about 72 hours, 72 hours and 96 hours, respectively, after injection.
  • the duration of action of the PEGylated single-chain G-CSF dimers is significantly longer than that of hG-CSF (Neupogen®).
  • the initial stimulation of white blood cell formation during the first 12 hours was identical in rats receiving hG-CSF (Neupogen®), SPA-PEG5000 conjugated single-chain G- CSF dimer, or SPA-PEG20000 conjugated single-chain G-CSF dimer.
  • WBC white blood cells
  • the level of white blood cells in the Neupogen-treated group reached normal levels (lOxlO 9 cells per litre) after 168 hours.
  • the level of white blood cells in the two groups treated with SPA-PEG 5000 conjugated single-chain G-CSF dimer and SPA-PEG 20000 conjugated single-chain G-CSF dimer dropped to a minimum of about 2xl0 9 cells per litre only after 48 hours.
  • the white blood cell levels in the two groups were back to normal after 144 hours and 120 hours, respectively.
  • the two PEG-conjugated single chain G-CSF dimer compounds were able to both relieve the degree of neutropenia and to reduce the time until the white blood cell levels were back to normal (the duration of neutropenia) significantly from 132 hours in the Neupogen®-treated group to 96 hours and 72 hours, respectively, in the groups treated with either SPA-PEG 5000 conjugated single chain G-CSF dimer or SPA-PEG 20000 conjugated single chain G-CSF dimer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des polypeptides multimères comportant une seule chaîne, comprenant au moins deux unités d'un polypeptide monomère reliées par l'intermédiaire d'une chaîne peptidique ou d'une liaison peptidique. Le polypeptide monomère est de type biologiquement actif sous forme monomère. L'invention concerne également des conjugués polypeptidiques comportant au moins une fraction non polypeptidique liée par covalence à un groupe de fixation du polypeptide. Le polypeptide est de préférence un dimère G-CSF (facteur stimulant les colonies de granulocytes) lié à une molécule polymère, de préférence à une ou plusieurs molécules de polyéthylèneglycol.
PCT/DK2001/000724 2000-11-02 2001-11-01 Polypeptides multimeres comportant une seule chaine WO2002036626A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002212108A AU2002212108A1 (en) 2000-11-02 2001-11-01 Single-chain multimeric polypeptides
EP01980207A EP1334127A1 (fr) 2000-11-02 2001-11-01 Polypeptides multimeres comportant une seule chaine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001647 2000-11-02
DKPA200001647 2000-11-02

Publications (1)

Publication Number Publication Date
WO2002036626A1 true WO2002036626A1 (fr) 2002-05-10

Family

ID=8159821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000724 WO2002036626A1 (fr) 2000-11-02 2001-11-01 Polypeptides multimeres comportant une seule chaine

Country Status (3)

Country Link
EP (1) EP1334127A1 (fr)
AU (1) AU2002212108A1 (fr)
WO (1) WO2002036626A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006501A3 (fr) * 2001-07-11 2004-03-25 Maxygen Holdings Ltd Conjugues de g-csf
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
EP1613644A1 (fr) * 2003-04-03 2006-01-11 Hanmi Pharm. Co., Ltd. Complexe homodimere peg-polypeptide physiologiquement actif a demi-vie prolongee in vivo et procede de preparation dudit complexe
WO2006128460A2 (fr) * 2005-06-01 2006-12-07 Maxygen Holdings Ltd. Polypeptides g-csf pegyles et procedes de production correspondants
US20110293554A1 (en) * 2010-05-25 2011-12-01 Generon (Shanghai) Corporation Ltd. Recombinant human g-csf dimer and use thereof for the treatment of neurological diseases
WO2012028093A1 (fr) * 2010-08-31 2012-03-08 健能隆医药技术（上海）有限公司 Utilisation d'un dimère de g-csf dans le traitement de la neutropénie
WO2013013613A1 (fr) * 2011-07-25 2013-01-31 健能隆医药技术（上海）有限公司 Utilisation d'un dimère g-csf dans la préparation d'un médicament pour le traitement de maladies neurodégénératives
WO2013022328A1 (fr) * 2011-08-09 2013-02-14 Uab Profarma Dérivés de protéines recombinantes, homomultimères du facteur de stimulation de colonie de granulocytes et leur procédé de préparation
EP2707021A4 (fr) * 2011-05-09 2015-08-05 Minerva Biotechnologies Corp Variants de facteur de croissance génétiquement modifiés
WO2016200645A1 (fr) * 2015-06-12 2016-12-15 Tianxin Wang Procédés pour la modification de protéines dans des applications pharmaceutiques
US9815879B2 (en) 2005-07-15 2017-11-14 Sandoz Ag Method for the purification of G-CSF
CN110582515A (zh) * 2018-11-12 2019-12-17 天境生物科技(上海)有限公司 包含cd47抗体和细胞因子的融合蛋白
US10610571B2 (en) 2017-08-03 2020-04-07 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
US11077195B2 (en) 2019-02-06 2021-08-03 Synthorx, Inc. IL-2 conjugates and methods of use thereof
US11834689B2 (en) 2017-07-11 2023-12-05 The Scripps Research Institute Incorporation of unnatural nucleotides and methods thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017185A1 (fr) * 1993-01-28 1994-08-04 Amgen Inc. Compositions analogues de g-csf et procedes
WO1996005224A1 (fr) * 1994-08-12 1996-02-22 Washington University Formes monocatenaires du quadruplet d'hormones de glycoproteine
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes
WO1996040772A2 (fr) * 1995-06-07 1996-12-19 Ortho Pharmaceutical Corporation Dimeres peptidiques d'agonistes
EP0783003A1 (fr) * 1995-04-26 1997-07-09 Kyowa Hakko Kogyo Co., Ltd. Nouveaux polypeptides
US5684136A (en) * 1992-05-18 1997-11-04 Genentech, Inc. Chimeric hepatocyte growth factor (HGF) ligand variants
WO1999002710A1 (fr) * 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Production et utilisation de multimeres de proteines recombinees a activite biologique modifiee
WO1999067291A2 (fr) * 1998-06-22 1999-12-29 Immunex Corporation Modification de proteine specifique a un site par mutagenese

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684136A (en) * 1992-05-18 1997-11-04 Genentech, Inc. Chimeric hepatocyte growth factor (HGF) ligand variants
WO1994017185A1 (fr) * 1993-01-28 1994-08-04 Amgen Inc. Compositions analogues de g-csf et procedes
WO1996005224A1 (fr) * 1994-08-12 1996-02-22 Washington University Formes monocatenaires du quadruplet d'hormones de glycoproteine
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes
EP0783003A1 (fr) * 1995-04-26 1997-07-09 Kyowa Hakko Kogyo Co., Ltd. Nouveaux polypeptides
WO1996040772A2 (fr) * 1995-06-07 1996-12-19 Ortho Pharmaceutical Corporation Dimeres peptidiques d'agonistes
WO1999002710A1 (fr) * 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Production et utilisation de multimeres de proteines recombinees a activite biologique modifiee
WO1999067291A2 (fr) * 1998-06-22 1999-12-29 Immunex Corporation Modification de proteine specifique a un site par mutagenese

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANCIS G E ET AL: "PEGYLATION OF CYTOKINES AND OTHER THERAPEUTIC PROTEINS AND PEPTIDES: THE IMPORTANCE OF BIOLOGICAL OPTIMISATION OF COUPLING TECHNIQUES", INTERNATIONAL JOURNAL OF HEMATOLOGY,ELSEVIER SCIENCE PUBLISHERS,NL, vol. 68, no. 1, 1998, pages 1 - 18, XP000907109, ISSN: 0925-5710 *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
WO2003006501A3 (fr) * 2001-07-11 2004-03-25 Maxygen Holdings Ltd Conjugues de g-csf
EP1613644A4 (fr) * 2003-04-03 2008-01-16 Hanmi Pharm Ind Co Ltd Complexe homodimere peg-polypeptide physiologiquement actif a demi-vie prolongee in vivo et procede de preparation dudit complexe
EP1613644A1 (fr) * 2003-04-03 2006-01-11 Hanmi Pharm. Co., Ltd. Complexe homodimere peg-polypeptide physiologiquement actif a demi-vie prolongee in vivo et procede de preparation dudit complexe
JP2013010765A (ja) * 2005-06-01 2013-01-17 Maxygen Inc Ｐｅｇ化されたｇ−ｃｓｆポリペプチドおよびその製造方法
JP2008542311A (ja) * 2005-06-01 2008-11-27 マキシゲン・ホールディングズ・リミテッド Ｐｅｇ化されたｇ−ｃｓｆポリペプチドおよびその製造方法
US7655766B2 (en) 2005-06-01 2010-02-02 Carsten Germansen Compositions comprising positional isomers of PEGylated G-CSF
CN101193658B (zh) * 2005-06-01 2011-08-31 马克西根控股公司 聚乙二醇化g-csf多肽及其产生方法
WO2006128460A3 (fr) * 2005-06-01 2007-03-01 Maxygen Holdings Ltd Polypeptides g-csf pegyles et procedes de production correspondants
WO2006128460A2 (fr) * 2005-06-01 2006-12-07 Maxygen Holdings Ltd. Polypeptides g-csf pegyles et procedes de production correspondants
US10844103B2 (en) 2005-07-15 2020-11-24 Mylan Pharmaceuticals Inc. Method for the purification of G-CSF
US9815879B2 (en) 2005-07-15 2017-11-14 Sandoz Ag Method for the purification of G-CSF
EP1904522B2 (fr) † 2005-07-15 2020-05-27 Mylan Pharmaceuticals Inc. Procede de purification du facteur g-csf
WO2011147319A1 (fr) * 2010-05-25 2011-12-01 Generon (Shanghai) Corporation Ltd. Dimère de g-csf humaine recombinante et son emploi dans le traitement de maladies neurologiques
CN102906120A (zh) * 2010-05-25 2013-01-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体及其在治疗神经***疾病中的用途
CN104710535A (zh) * 2010-05-25 2015-06-17 健能隆医药技术（上海）有限公司 重组人g-csf二聚体及其在治疗神经***疾病中的用途
EP2576624A1 (fr) * 2010-05-25 2013-04-10 Generon (Shanghai) Corporation Ltd. Dimère de g-csf humaine recombinante et son emploi dans le traitement de maladies neurologiques
JP2013530148A (ja) * 2010-05-25 2013-07-25 ジェネロン （シャンハイ） コーポレーション エルティーディー． 組換えヒトｇ−ｃｓｆ二量体およびその神経系疾患の治療における用途
US8557546B2 (en) * 2010-05-25 2013-10-15 Generon (Shanghai) Corporation Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases
EP2576624A4 (fr) * 2010-05-25 2013-11-13 Generon Shanghai Corp Ltd Dimère de g-csf humaine recombinante et son emploi dans le traitement de maladies neurologiques
CN104710535B (zh) * 2010-05-25 2018-10-16 健能隆医药技术（上海）有限公司 重组人g-csf二聚体及其在治疗神经***疾病中的用途
US20110293554A1 (en) * 2010-05-25 2011-12-01 Generon (Shanghai) Corporation Ltd. Recombinant human g-csf dimer and use thereof for the treatment of neurological diseases
EP3121198A1 (fr) * 2010-05-25 2017-01-25 Generon (Shanghai) Corporation Ltd. Dimère g-csf humain de recombinaison et son utilisation pour le traitement de maladies neurologiques
US9273108B2 (en) 2010-05-25 2016-03-01 Generon (Shanghai) Corporation Ltd. Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases
CN102906120B (zh) * 2010-05-25 2015-03-04 健能隆医药技术（上海）有限公司 重组人g-csf二聚体及其在治疗神经***疾病中的用途
AU2011257734B2 (en) * 2010-05-25 2015-06-11 Evive Biotechnology (Shanghai) Ltd Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases
WO2012028093A1 (fr) * 2010-08-31 2012-03-08 健能隆医药技术（上海）有限公司 Utilisation d'un dimère de g-csf dans le traitement de la neutropénie
EP3028713A1 (fr) * 2010-08-31 2016-06-08 Generon (Shanghai) Corporation Ltd. Utilisation de g-csf dimèrique dans le traitement de la neutropénie
EP2707021A4 (fr) * 2011-05-09 2015-08-05 Minerva Biotechnologies Corp Variants de facteur de croissance génétiquement modifiés
CN103732240A (zh) * 2011-07-25 2014-04-16 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用
JP2014521612A (ja) * 2011-07-25 2014-08-28 ジェネロン（シャンハイ）コーポレイション リミテッド 神経変性疾患を治療する医薬品の製造におけるｇ−ｃｓｆ二量体の応用
WO2013013613A1 (fr) * 2011-07-25 2013-01-31 健能隆医药技术（上海）有限公司 Utilisation d'un dimère g-csf dans la préparation d'un médicament pour le traitement de maladies neurodégénératives
US9642917B2 (en) 2011-07-25 2017-05-09 Generon (Shanghai) Corporation, Ltd. Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases
CN103732240B (zh) * 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用
US9243049B2 (en) 2011-08-09 2016-01-26 Uab Profarma Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
US20140193357A1 (en) * 2011-08-09 2014-07-10 Uab Profarma Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
WO2013022328A1 (fr) * 2011-08-09 2013-02-14 Uab Profarma Dérivés de protéines recombinantes, homomultimères du facteur de stimulation de colonie de granulocytes et leur procédé de préparation
CN103717614A (zh) * 2011-08-09 2014-04-09 普罗法尔马封闭式股份公司 重组蛋白质的衍生物、粒细胞集落刺激因子的同多聚体及其制备方法
CN108431018A (zh) * 2015-06-12 2018-08-21 王天欣 药物应用中蛋白质修饰的方法
WO2016200645A1 (fr) * 2015-06-12 2016-12-15 Tianxin Wang Procédés pour la modification de protéines dans des applications pharmaceutiques
US11834689B2 (en) 2017-07-11 2023-12-05 The Scripps Research Institute Incorporation of unnatural nucleotides and methods thereof
US10610571B2 (en) 2017-08-03 2020-04-07 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
US11701407B2 (en) 2017-08-03 2023-07-18 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
US11622993B2 (en) 2017-08-03 2023-04-11 Synthorx, Inc. Cytokine conjugates for the treatment of autoimmune diseases
CN110582515A (zh) * 2018-11-12 2019-12-17 天境生物科技(上海)有限公司 包含cd47抗体和细胞因子的融合蛋白
US11077195B2 (en) 2019-02-06 2021-08-03 Synthorx, Inc. IL-2 conjugates and methods of use thereof

Also Published As

Publication number Publication date
AU2002212108A1 (en) 2002-05-15
EP1334127A1 (fr) 2003-08-13

Similar Documents

Publication Publication Date Title
US20020142964A1 (en) Single-chain polypeptides
US6646110B2 (en) G-CSF polypeptides and conjugates
EP1250154B1 (fr) Produits conjugues g-csf
US6555660B2 (en) G-CSF conjugates
JP4444652B2 (ja) Ｇ−ｃｓｆ結合体
AU2002325819A1 (en) G-CSF Conjugates
WO2002036626A1 (fr) Polypeptides multimeres comportant une seule chaine
US6831158B2 (en) G-CSF conjugates
RU2290411C2 (ru) Конъюгаты g-csf

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001980207

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001980207

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001980207

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP